HER2-abstracts

474 abstracts

Abstract CT059 / 17 - StrataPATHTM: a multicohort, non-randomized, open-label phase 2 trial to explore efficacy and safety of FDA-approved cancer therapies in novel biomarker-guided patient population Indication:Acute Myeloid Leukem...,Product:Durvalumab,Lorlatinib,Binimetinib + Encora..., Search all connections
Abstract https://www.abstractsonline.com/pp8/#!/10828/presentation/10501 Indication:Breast Cancer,Product:GLSI-100,Trastuzumab deruxtec...,Drug:trastuzumab deruxtec...,GLSI-100,Target:HER2 (ERBB2), Search all connections
Abstract https://www.nejm.org/doi/10.1056/NEJMoa2115022 Clinical trial:DS8201-A-U302,Indication:Breast Cancer,Product:Trastuzumab deruxtec...,T-DM1,Drug:trastuzumab emtansin...,trastuzumab deruxtec...,Target:HER2 (ERBB2), Search all connections
Abstract Phase II trial of rifaximin in patients with early-stage HER2 positive breast cancer with gastrointestinal toxicities related to pertuzumab-based therapy. Clinical trial:MC18C3,Organization:Mayo Clinic,H. Lee Moffitt Cance...,Mayo Clinic Florida,Drug:pertuzumab,rifaximin,docetaxel, Search all connections
Abstract Early integration of exercise into breast cancer care: The MSK Healthy Living program. Organization:Memorial Sloan Kette...,Drug:Cisplatin,radiation,Androgen deprivation...,Target:Estrogen Receptors (...,Progesterone recepto...,DNA cells, Search all connections
Abstract Cost-effectiveness of novel systemic therapies for advanced breast cancer: Global representativeness and influence of funding. Organization:Instituto do Câncer ...,University of São Pa...,São Paulo, SP, Brazi..., Search all connections
Abstract Evolution of cancer treatment costs in the last 36 months in a self-funded health care in Brazil. Organization:CAPESESP,Drug:nivolumab,daratumumab,bevacizumab, Search all connections
Abstract Male breast cancer survival data and clinicopathological characteristics: A single-centre experience. Organization:Hospital Agios Savva...,Agios Savvas Cancer ...,Saint Savvas Hospita...,Drug:anthracyclines,taxane, Search all connections
Abstract Cancer therapy-associated thrombosis: A patient- reported outcomes (PROs) analysis. Organization:Care Across,Drug:aromatase inhibitors,Tamoxifen,Trastuzumab, Search all connections
Abstract Real-world data on incidence of acute adverse reactions (AARs) reported in clinical practice. Organization:Medical Day Hospital...,Medical Day Hospital...,Pharmacy Unit Fondaz...,Drug:mFOLFOX6,liposomal doxorubici...,etoposide, Search all connections
Abstract Genomic landscape of cancer of unknown primary site (CUP): Mayo Clinic experience. Organization:Mayo Clinic,Mayo Clinic, Departm...,Mayo Clinic, Mankato,Drug:BRCA2,NF1 ATM,HER2/NEU, Search all connections
Abstract Prognostic stratification and outcome of metastatic NSCLC based on activating mutation profile and PD-L1 status. Organization:The University of Te...,UTHealth Houston,McGovern Medical Sch...,Drug:KRAS,EGFR-tyrosine kinase...,HER2 CAR-T,Product:TMZ,Target:HER2 (ERBB2), Search all connections
Abstract The impact of the COVID-19 pandemic on the diagnosis and treatment of breast cancer at a community hospital. Organization:Gundersen Health Sys...,Gundersen Medical Ce...,Drug:Cisplatin,Androgen deprivation...,Target:HER2 (ERBB2),Estrogen Receptor (E...,progesterone recepto...,Congress:ASCO 2023, Search all connections
Abstract Area deprivation index and breast cancer subtypes in young patients. Organization:Ochsner Medical Cent...,Ochsner Health Syste...,Ochsner Clinic Found...,Drug:ER+/HER2-,ER-/HER2- (TNBC),ER-/HER2+,Target:HER2 (ERBB2), Search all connections
Abstract The impact of novel therapies on disparities in survival outcomes for metastatic cancers. Organization:Lumen Value & Access,Healthcare Consultan...,Drug:metastatic breast ca...,metastatic colorecta...,metastatic non-small...,Target:HER2 (ERBB2),PRMT5,Congress:ASCO 2023, Search all connections
Abstract Real world evidence for continuing HER2-directed therapy for metastatic breast cancer. Organization:BC Cancer-Vancouver ...,B.C. Cancer Agency,University of Toront...,Drug:Trastuzumab,pertuzumab,TDM-1, Search all connections
Abstract Does community size impact survival with breast cancer? Data from a large population-based cohort in British Columbia. Organization:BC Cancer-Vancouver ...,British Columbia Bre...,Breast Cancer Outcom...,Drug:Cisplatin,endocrine therapy, Search all connections
Abstract Breaking down the divide: An analysis of male breast cancer demographics and survival by race. Organization:The Wright Center fo...,University of Texas ...,Geisinger Health Sys...,Drug:Erwinia asparaginase,Tiragolumab,HER2 CAR-T,Target:HER2 (ERBB2),PRMT5, Search all connections
Abstract Defining the patient population with HER2-low breast cancer in Hawaii. Organization:University of Hawaii...,John A Burns School ...,Kapiolani Medical Ce...,Drug:HER2-directed antibo...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Breast cancer brain metastases: the Graded Prognostic Assessment index (GPA) in a real-world low- and middle-income (LMIC) population. Organization:Instituto Nacional d...,Instituto Nacional d...,Drug:HER2 CAR-T,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Deep multi-omic analyses to identify targetable pathways in desmoplastic small round cell tumor (DSRCT) with opportunities for clinical intervention. Organization:OHSU Knight Cancer I...,Portland, OR,Oregon Health & Scie...,Drug:HER2 CAR-T,androgen receptor pa...,DNA damage response, Search all connections
Abstract Clinical outcomes of extramammary Paget’s disease in Korea: A multicenter, retrospective study. Organization:Inje University Sang...,Asan Medical Center,Seoul National Unive..., Search all connections
Abstract Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC) therapy. Organization:Key Laboratory of Ca...,National Cancer Cent...,Department of Medica...,Drug:Disitamab vedotin,Tiragolumab, Search all connections
Abstract Oncomine Dx Express CE-IVD liquid biopsy assay for non-small cell lung cancer: Performance review and analytical validation. Organization:Thermo Fisher Scient...,Austin Health,Txinno Bioscience,Drug:ERBB2,EGFR-tyrosine kinase...,KRAS, Search all connections
Abstract Reality check for precision oncology in squamous cell lung cancer. Organization:UAMS-Winthrop Rockef...,UAMS Medical College...,Drug:EGFR-tyrosine kinase...,Melphalan,ROS1 TKIs,Product:TMZ, Search all connections
Abstract Prevalence of actionable oncogenic alterations (AGA) among patients with advanced (adv) non-squamous (NSQ) non-small cell lung cancer (NSCLC) by age, sex, and race in the United States (US). Organization:Merck & Co, Inc.,Merck & Co., Inc.,Merck and Co, Inc.,Drug:EGFR mutation,ALK rearrangement,KRAS G12C mutation, Search all connections
Abstract Liquid and tissue profiling of targetable co-mutations with KRAS in non-small cell lung cancer. Organization:Fortis Cancer Instit...,Rajiv Gandhi Cancer ...,Tata Memorial Centre,Drug:EGFR TKI,Osimertinib, Search all connections
Abstract Biomarkers to predict the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer with actionable genetic alterations. Organization:SAIHST,Sungkyunkwan Univers...,Samsung Medical Cent...,Drug:Immune checkpoint in...,ICIs,Target:CTLA-4,PD-1,ROS1, Search all connections
Abstract Restaging scans frequency heterogeneity in patients being treated for stage IV non-small cell lung cancer (NSCLC). Organization:Mayo Clinic, Jackson...,Drug:Melphalan,BRAF V600E,EGFR-tyrosine kinase...,Product:TMZ, Search all connections
Abstract UCLA l-08: A phase ib/II study of combined HER inhibition adding necitumumab and trastuzumab to osimertinib in patients with refractory EGFR-mutated lung cancer. Clinical trial:19-002190,Organization:David Geffen School ...,Weizmann Institute o...,Drug:Osimertinib,necitumumab,Trastuzumab,Target:HER2 (ERBB2),EGFR-TKI sensitizing..., Search all connections
Abstract Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: The IMMINENT study. Organization:University of Verona...,Azienda Ospedaliera ...,Ospedale San Bortolo..., Search all connections
Abstract Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world study. Organization:National Cancer Cent...,National Clinical Re...,Cancer Hospital of C...,Drug:pyrotinib,apatinib,Anlotinib, Search all connections
Abstract Genomic profiling of cerebrospinal fluid ctDNA to characterize molecular features and monitor intracranial responses of patients with osimertinib-resistant non-small cell lung cancer with leptomeningeal metastases. Organization:3D Medicines Inc.,Drug:Osimertinib,Target:BRAF,BRCA2,ALK, Search all connections
Abstract Genomic profiling in advanced NSCLC in Italy: First results of NERoNE (NSCLC Emilia Romagna Next Generation Sequencing Evaluation) project. Organization:University of Modena...,Medical Oncology Uni...,IRCCS Istituto Romag...,Drug:EGFR-tyrosine kinase...,KRAS, Search all connections
Abstract Prognostic effects of TP53 variants co-occuring in patients with HER2-mutated non-small cell lung cancer (NSCLC). Organization:Princess Margaret Ca...,University Health Ne...,Toronto, ON, Canada, Search all connections
Abstract Does the landscape of comprehensive genomic profiling in patients with advanced stage lung cancer in India differ from data from the western countries. Organization:Fortis Cancer Instit...,Fortis Cancer Instit...,Fortis Cancer Instit...,Drug:EGFR-tyrosine kinase...,Melphalan,ROS1 TKIs, Search all connections
Abstract Genomic biomarker testing and treatment in advanced NSCLC: Practice patterns and barriers in a global survey of oncology point-of-care mobile app users. Organization:Siyemi Learning,ONCOassist,Department of Oncolo...,Drug:EGFR-tyrosine kinase...,Melphalan,ROS1 TKIs, Search all connections
Abstract Tumor immune microenvironment in BRAF V600E mutant lung adenocarcinoma. Organization:Department of Medica...,Drug:BRAF V600E,Melphalan,BRAF,Product:TMZ, Search all connections
Abstract Comparative analysis of the mutation detection using malignant pleural effusion and blood cell-free DNA samples in lung cancer. Organization:Department of Thorac...,Department of Oncolo...,Department of Oncolo...,Drug:EGFR-tyrosine kinase...,KRAS,BRAF, Search all connections
Abstract Pembrolizumab immunotherapy in advanced and recurrent/metastatic salivary gland carcinoma (R/M SGC): A systematic review and meta-analysis. Organization:Federal University o...,Pelotas, Brazil,Brazil,Drug:pembrolizumab,nivolumab,ipilimumab, Search all connections
Abstract Comprehensive genomic analysis of salivary gland carcinomas in a Chinese population. Organization:Department of Oral a...,Shanghai OrigiMed Co...,Drug:ERBB2,PIK3CA,ATM, Search all connections
Abstract The genomic landscape and prognostic significance of 11.q.13 amplification in breast, head & neck, and lung cancer. Organization:Caris Life Sciences,...,Hoag Memor Hosp,University of Cincin...,Drug:FGF3,FGF4,FGF19, Search all connections
Abstract The association of progesterone receptor and abnormal p53 expression in endometrioid endometrial cancer. Organization:Linkou Chang Gung Me...,Department of Pathol...,Chang Gung Memorial ...,Drug:p53, Search all connections
Abstract The impact of ImmunoPrecision in small bowel adenocarcinoma. Organization:Cedars-Sinai The Ang...,University of New Me...,Texas Oncology-Austi...,Drug:immunotherapy, Search all connections
Abstract Assessing the Discordance Rate of HER2 expression by Immunohistochemistry between Primary and Secondary Prostate Cancer Biopsies. Organization:Washington DC Vetera...,Washington DC VA Med...,The George Washingto...,Drug:VENTANA anti-HER2/ne...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract The efficacy and safety of antibody drug conjugate for high-risk non-muscle-invasive bladder cancer. Organization:Tianjin Medical Univ...,The Second Hospital ...,Tianjin Hemay Pharma...,Drug:RC48,tislelizumab,Target:HER2 (ERBB2),PD-1,Congress:ASCO 2023, Search all connections
Abstract Performance of the OncoUrine test on the predictive capacity of non-muscle-invasive bladder cancer patients who are candidates for repeated transurethral resection. Organization:Department of Urolog...,Jichenjunchuang Medi...,The First Affiliated...,Drug:OncoUrine,TERT,TP53, Search all connections
Abstract Enhanced detection and characterization of targetable EGFR and ERBB2 exon20 insertion mutations in urothelial carcinoma. Organization:University of North ...,UNC Hosps,University of North ...,Drug:Mobocertinib,Erlotinib, Search all connections
Abstract Precision medicine applied to rare malignancies: A single-center experience at University Hospital of Verona. Organization:Medical Oncology Gro...,Azienda Ospedaliera ...,Investigational Canc..., Search all connections
Abstract EGFR/ERBB2 aberrations in Chinese biliary tract carcinomas. Organization:Eastern Hepatobiliar...,Nanjing Simcere Medi...,The Medical Departme...,Drug:EGFR-tyrosine kinase...,ERBB2,Target:HER2 (ERBB2),EGFR-TKI sensitizing...,Congress:ASCO 2023, Search all connections
Abstract Anti–PD-1 combination regimen as first-line therapy in advanced biliary tract cancer and biomarker exploration: A retrospective study. Organization:The Comprehensive Ca...,Clinical Cancer Inst...,Department of Radiol...,Drug:anti-PD-1,Cisplatin, Search all connections
Abstract Efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2-positive resectable gastric/gastroesophageal junction cancer (GC/EGJC): Preliminary results of a phase 2, single-arm trial. Clinical trial:TIS-HER2GC-PERIOPERA...,Organization:First Affiliated Hos...,Department of Medica...,Anyang Tumor Hospita...,Drug:tislelizumab,Trastuzumab,docetaxel, Search all connections
Abstract The mutational landscape of circulating cell free DNA in patients with gastric cancer. Organization:The First Affiliated...,Department of Oncolo...,The First Affiliated...,Drug:TP53,LRP1B,ARID1A, Search all connections
Abstract Updated results of the phase 1 I-FLOAT trial: Safety and efficacy of combining genotype-guided irinotecan with 5FU, leucovorin, oxaliplatin and docetaxel (gFOLFOXIRITAX) in advanced upper GI cancers. Clinical trial:IRB19-1292,Organization:University of Chicag...,University of Chicag...,Department of Medici..., Search all connections
Abstract Assessing the real-world experience of treating gastric cancer in Armenia: A retrospective-study. Organization:Immune Oncology Rese...,Pediatric Cancer and...,Hematology Center Af..., Search all connections
Abstract Predictors of resistance to trastuzumab deruxtecan (T-DXd) in esophagogastric adenocarcinoma (EGC). Organization:Weill Cornell Medica...,Department of Epidem...,Memorial Sloan Kette...,Drug:mFOLFOXIRI,Target:HER2 (ERBB2),topoisomerase I, Search all connections
Abstract First-line envafolimab plus SOX chemotherapy for PD-L1 positive metastatic or recurrent gastric adenocarcinoma: A multi-centre, single-arm phase II clinical trial. Clinical trial:SMA-GC-001,Organization:Jiangsu Cancer Hospi...,Nanjing Yoko Biomedi...,Drug:Envafolimab,SOX,mFOLFOX6,Target:HER2 (ERBB2), Search all connections
Abstract Identification of novel actionable SNVs via targeted comprehensive genome profiling in patients with gallbladder and cholangiocarcinoma cancer. Organization:Bhaktivedanta Hospit...,MIT WPU,OneCell Dx, Search all connections
Abstract Differences of RAS/BRAF mutations between ISCC and RSCC in a Chinese population. Drug:ERBB2 targeting agen...,ARID2,BRIP1,Target:HER2 (ERBB2),ARID2,BRIP1,Organization:the General Hospital...,AcornMed Biotechnolo..., Search all connections
Abstract Clinical and molecular characterization of HER2-low metastatic colorectal cancer. Organization:Hadassah-Hebrew Univ...,Dana-Farber Cancer I...,Drug:HER2-directed antibo...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Prognosis of patients with HER2-low breast cancer brain metastasis: A single-institution experience. Organization:National Cancer Cent...,National Clinical Re...,Cancer Hospital of C...,Drug:trastuzumab deruxtec...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Preliminary results of a phase I, first-in-human, dose escalation study of IMM2902 in patients with HER2-expressing advanced solid tumors. Organization:Phase I Clinical Tri...,Fudan University Sha...,Shanghai, China, Gra..., Search all connections
Abstract Negative selection of patients (pts) with HER2-positive and RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving dual HER2 blockade. Organization:Department of Medica...,Department of Gastro...,Memorial Sloan Kette..., Search all connections
Abstract Identification of clinically actionable biomarkers in an Indian cancer cohort using comprehensive genomic profiling (CGP): An institutional experience. Organization:Triesta Sciences,HCG Cancer Center Mu...,Strand Life Sciences,Drug:PARP inhibitors,EGFR-tyrosine kinase...,RAS/RAF, Search all connections
Abstract Comprehensive genomic profiling and therapeutic implications for patients with advanced cancers: The experience of an academic hospital. Organization:Department of Oncolo...,Antwerp University H...,University Hospital ...,Drug:ERBB2,KRAS,PIK3CA, Search all connections
Abstract Use of CLIA accredited multi-omic platforms to correlate clinical significance of WES/WTS testing with functional protein/phosphoprotein drug target activity. Organization:Avera Cancer Institu...,Theralink Technologi...,George Mason Univers...,Drug:trastuzumab deruxtec...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Impact of overfixation on actionable biomarkers and checkpoint inhibitor (CKI) targets with immunohistochemistry (IHC) in a patient population with non-small cell lung cancer (NSCLC). Organization:Cerba Research,Montpellier Cancer I...,France, Search all connections
Abstract Copy number variation (CNV) calling of MET, MYC, and ERBB2 using PiVAT bioinformatic platform. Organization:Shanghai Zhengu Biol...,Pillar Biosciences I...,Product:TMZ,Drug:mycophenolate,ERBB2,Target:HER2 (ERBB2),MYC,metastatic breast ca..., Search all connections
Abstract A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive, heavily pretreated solid tumors: Results from a phase Ⅰa/Ⅰb, first-in-human, open-label, single-center study. Clinical trial:IAH0968-I/IIa,Organization:The First Hospital o...,Shenyang Sunshine Ph...,China National Biote...,Drug:IAH0968,Trastuzumab,Target:HER2 (ERBB2), Search all connections
Abstract RNA sequencing as a confirmatory assay and its impact on patient care in multiple cancer types. Organization:Weill Cornell Medici...,Englander Institute ...,New York Presbyteria...,Drug:Trastuzumab, Search all connections
Abstract Analytical performance assessment of ASPYRE-Lung: A new assay for rapid detection of actionable variants from tissue and plasma in NSCLC patients. Organization:Biofidelity Ltd,Drug:Melphalan,BRAF,EGFR-tyrosine kinase..., Search all connections
Abstract Analysis of cell-free DNA (cfDNA) fragmentomes and prediction scores across distinct molecular subtypes. Organization:Delfi Diagnostics, I...,DELFI Diagnostics,The Sidney Kimmel Co...,Drug:Melphalan, Search all connections
Abstract Methylated ctDNA as a biomarker for detecting previously undetectable clinically significant somatic mutations. Organization:BillionToOne, Inc.,UC San Diego Moores ...,Drug:ERBB2,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract No checkmate in metastatic setting: Navigating real world patients applying personalized therapy based on extensive tumor profiling. Organization:Datar Cancer Genetic...,Datar Cancer Genetic...,Novustat GmbH,Drug:sotorasib,margetuximab,FF-10832, Search all connections
Abstract Preclinical antitumor activity of an anti-HER2/Trop-2 bispecific antibody-drug conjugate with a new DNA topoisomerase I inhibitor. Organization:BiOneCure Therapeuti...,BiOneCure Therapeuti...,Drug:Enhertu,Sacituzumab goviteca...,BIO-201,Target:HER2 (ERBB2),Trop-2, Search all connections
Abstract Comparison of two ICI-based microtubule antagonist therapies for high-risk, non-muscle-invasive bladder cancer. Organization:The Second Hospital ...,Tianjin Hemay Pharma...,Second Hospital of T...,Drug:Abraxane,RC48-ADC,tislelizumab,Target:HER2 (ERBB2),PD-1, Search all connections
Abstract A multicenter, phase II trial of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor, GM-CSF, and sequential IL-2 (PRaG3.0 regimen) for salvage therapy in patients with HER2-expressing advanced solid tumors. Organization:Second Affiliated Ho...,Institution of Radio...,Soochow University,Drug:PRaG therapy,RC48-ADC,PD-1/L1 inhibitors, Search all connections
Abstract T cell redirecting and TLR7/8 agonist encapsulated liposomes targeting HER2+ tumors: Preclinical efficacy, pharmacokinetics and safety evaluations. Organization:Hangzhou Highfield B...,Clinical Trial Cente...,National Cancer Cent..., Search all connections
Abstract Development of a quantitative systems pharmacology (QSP) model to support dose optimization of DS-1103a (anti SIRPa antibody) in combination with trastuzumab deruxtecan in patients with cancer. Organization:Daiichi Sankyo Inc.,Certara Germany GmbH,Daiichi Sankyo Shina...,Drug:DS-1103a,trastuzumab deruxtec...,DS-8201a,Target:HER2 (ERBB2), Search all connections
Abstract Survival in patients with brain metastasis secondary to breast cancer from Saudi Arabia. Organization:Faculty of Medicine,...,King Abdulaziz Unive...,Jeddah,Drug:HER2-positive breast...,HR-positive,Target:HER2 (ERBB2),Hormone Receptors (H..., Search all connections
Abstract Knowledge gaps and educational needs for common cancer therapy-related cardiovascular toxicities and related drug interactions. Organization:UNC Eshelman School ...,Duke University Medi...,Baptist Health Syste...,Drug:anthracyclines, Search all connections
Abstract Pattern of molecular testing among US veterans with gastrointestinal cancers: A single center experience. Organization:Veterans Affairs Med...,Oklahoma City, OK,Oklahoma City VA Hea...,Drug:FDA-approved targete...,Target:TP53,KRAS G12C,HER2 (ERBB2), Search all connections
Abstract Alternative trastuzumab dosing schedules and association with health care greenhouse gas emissions. Organization:VA Center for Clinic...,Yale College,Pritzker School of M...,Drug:Trastuzumab,Target:HER2 (ERBB2), Search all connections
Abstract HER2 in situ hybridization testing in breast cancer: Applying algorithm-assisted assessment to reduce interobserver variability in difficult cases. Organization:Mater Health Service...,Mater Research Insti...,Centre for the Busin...,Drug:HER2 CAR-T, Search all connections
Abstract Characteristics and predictive modeling of HER2 mutation in patients with non-small cell lung cancer. Organization:Mayo Clinic,John Theurer Cancer ...,City of Hope Nationa...,Drug:KRAS,EGFR-tyrosine kinase...,Product:TMZ, Search all connections
Abstract Time to treatment in inflammatory breast cancer: Experience from a single institution. Organization:Ohio State Universit...,Center for Biostatis...,The Ohio State Unive...,Drug:neoadjuvant chemothe...,Target:HER2 (ERBB2),microtubules,DNA, Search all connections
Abstract Validation of a 56 gene panel for the detection of somatic variants in metastatic breast cancer. Organization:Epic Sciences, Inc.,Drug:PIK3CA,ESR1,BRCA1, Search all connections
Abstract Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial. Organization:University of Padua ...,Veneto Institute of ...,Arcispedale Santa Ma..., Search all connections
Abstract Trastuzumab-deruxtecan in HER2-low metastatic/unresectable breast cancer: Real life data in two Parisian centers. Organization:Hôpital Tenon,Institut Universitai...,Sorbonne Université, Search all connections
Abstract Clinical outcomes of patients with metastatic breast cancer treated with eribulin: A real-world evidence study from China. Organization:West China Hospital,Sichuan University,Breast Disease Cente...,Drug:eribulin,anti-HER2 targeted t...,immunotherapy, Search all connections
Abstract Efficacy of antibody-drug conjugates in breast cancer: A systematic review and meta-analysis of randomized clinical trials. Organization:Saint Mary's and Sai...,New York Medical Col...,Schulich School of M..., Search all connections
Abstract Treatment (Tx) patterns, efficacy and safety of eribulin for advanced and heavily pretreated breast cancer (ABC): A single-center, real-world study. Organization:Department of Medica...,First Affiliated Hos...,Drug:eribulin,bevacizumab,CAPOX,Target:HER2 (ERBB2),microtubule dynamics, Search all connections
Abstract Comparison of real-world outcomes over time in a large population-based cohort of patients with metastatic breast cancer. Organization:University of Britis...,BC Cancer-Vancouver ...,Department of Radiat...,Drug:pertuzumab,Trastuzumab,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Comprehensive molecular profiling from liquid and tissue for analysing the somatic mutational landscape in an Indian breast cancer cohort. Organization:Fortis Cancer Instit...,Sir H N Reliance Fou...,BALCO Medical Center, Search all connections
Abstract Clinicopathological characteristics, evolution, treatment patterns and outcomes of hormone-receptor-positive/HER2-low-positive metastatic breast cancer: A retrospective analysis. Organization:Department of Breast...,Fudan University Sha...,Drug:endocrine therapy,Cisplatin,Target:HER2 (ERBB2),Hormone receptors,Congress:ASCO 2023, Search all connections
Abstract Impact of use of CDK4/6i and neratinib among patients with HER2 +ve MBC: Results from a real world dataset. Organization:Mediclinic City Hosp...,TriNetX Europe,Drug:CDK4/6i,neratinib,Trastuzumab, Search all connections
Abstract ERBB2 (HER2) gene amplification concordance analysis of circulating tumor cells and tumor tissue in patients with breast cancer. Organization:UC San Diego Moores ...,Biofluidica,Biomatrica, Inc.,Drug:HER2 monoclonal anti...,HER2 tyrosine kinase...,HER2 antibody drug c...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Comparing digital and glass slide methods for determining the HER2-low and negative categories in breast cancer. Organization:National Cancer Cent...,National Clinical Re...,Cancer Hospital of C..., Search all connections
Abstract De novo metastatic Her2+ breast cancer in a diverse population of women under age 40. Organization:Ochsner Medical Cent...,Ochsner Health Syste...,Ochsner Health Cente...,Drug:Her2-directed therap...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Palbociclib, trastuzumab, pyrotinib and fulvestrant in patients with brain metastasis from ER/PR positive, HER-2 positive breast cancer: Report from an interim analysis of a multicenter, prospective study in China. Organization:Department of Medica...,State Key Laboratory...,Collaborative Innova..., Search all connections
Abstract Shifting trends in the usage of trastuzumab with its biosimilar inception in India. Organization:Mylan Pharmaceutical...,Viatris,Drug:Trastuzumab,pertuzumab,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Pyrotinib maleate for the treatment of brain metastases from HER2-positive solid tumours: A real-world study. Organization:Beijing Tian Tan Hos...,Capital Medical Univ...,Beijing InnoCare Pha...,Drug:pyrotinib,pyrrolizidine,Target:HER2 (ERBB2),HER1,HER4, Search all connections
Abstract A disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2+ unresectable locally advanced or metastatic breast cancer (aBC): Interim results of the ESTHER study (NCT02393924). Organization:Roche Products Limit...,Cmed Clinical Resear...,Leeds Institute of M..., Search all connections
Abstract Real-world outcomes of long-term efficacy of T-DM1 after discontinuation due to limiting toxicity in patients with HER2-positive metastatic breast cancer. Organization:Hospital Beneficênci...,Drug:T-DM1,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Safety and efficacy study of oral metronomic capecitabine in combination with pyrotinib for HER2‑positive metastatic breast cancer: A phase II trial. Organization:National Cancer Cent...,National Clinical Re...,Cancer Hospital of C...,Drug:CAPOX,pyrotinib,Target:HER2 (ERBB2), Search all connections
Abstract ADC vs HP dual-antibody for HER2-positive advanced breast cancer after failed to TKI. Organization:Department of Oncolo...,The Fifth Medical Ce...,Fifth Medical Center...,Drug:TKI,ARX788, Search all connections
Abstract Incidence of interstitial lung disease and cardiotoxicity with trastuzumab-deruxtecan in patients with breast cancer: A systematic review and single-arm meta-analysis. Organization:Federal University o...,Princess Margaret Ho...,Dona Íris Hospital a...,Drug:trastuzumab-deruxtec...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Real-life experience of trastuzumab deruxtecan (T-DXd) in patients with heavily pretreated HER2 positive advanced breast cancer: A retrospective single institution study. Organization:University of Califo...,UC Irvine Health,Chao Family Comprehe...,Drug:Tucatinib,Trastuzumab, Search all connections
Abstract Effect of suppressing the p38 pathway through upregulation of Wip1 on Her2 early dissemination of breast cancer. Organization:Wake Forest Baptist ...,Tianjin Medical Univ...,Drug:HER2 CAR-T,Wip1,Skp2,Target:Skp2,Wip1,MK2, Search all connections
Abstract Construction of a prognostic hierarchical model for patients with HER2 positive breast cancer with brain metastases. Organization:The Fifth Medical Ce...,Chinese PLA General ...,Fujian Provincial Ke...,Drug:Trastuzumab,pertuzumab,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Combination of eribulin with trastuzumab and pertuzumab for HER2 positive advanced or recurrent breast cancer: JBCRGM03. Organization:Kanagawa Cancer Cent...,Matsuyama Red Cross ...,Nagoya University Gr..., Search all connections
Abstract Real-world safety and effectiveness of CT-P6 (biosimilar trastuzumab): A post-marketing surveillance study in Korea. Organization:Chonnam National Uni...,Inje University Busa...,Korea University Gur..., Search all connections
Abstract Preliminary analysis of pyrotinib and dalpiciclib-based therapy in HER2-positive advanced breast cancer (ABC). Organization:Shandong Cancer Hosp...,Shandong University ...,Jinan, China, Search all connections
Abstract Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: A systematic review and network meta-analysis. Organization:National Cancer Cent...,National Clinical Re...,Cancer Hospital of C...,Drug:endocrine therapy,Trastuzumab,pertuzumab, Search all connections
Abstract Radiotherapy combined with pyrotinib plus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and brain metastases: A single-arm, exploratory trial. Organization:Department of Radiot...,Department of Breast...,Department of Breast...,Drug:pyrotinib,CAPOX,Trastuzumab,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Characterization of patients with recurrent breast cancer submitted to neoadjuvant therapy in a Brazilian cancer center. Organization:A.C. Camargo Cancer ...,Hospital ACCamargo,A.C. Camargo Hospita...,Drug:anthracyclines,taxane,Trastuzumab, Search all connections
Abstract A combination of circulating tumor cell (CTC) and cancer stem cell (CSC) markers to predict the prognosis of breast cancer. Organization:Baylor College of Me...,The University of Te...,University of Texas ...,Drug:EpCAM CAR-T,MUC-1,HER2 CAR-T, Search all connections
Abstract Neoadjuvant endocrine therapy for early-stage breast cancer: An institutional experience during the COVID19 pandemic. Organization:Dartmouth-Hitchcock ...,Dartmouth College Ge...,Dartmouth Geisel Med...,Drug:neoadjuvant endocrin...,aromatase inhibitor,Target:HER2 (ERBB2),Estrogen Receptors (...,aromatase, Search all connections
Abstract De-escalating therapy dilemma in small HER2 positive node negative breast cancer. Organization:Centre Oscar Lambret,Drug:Trastuzumab,anthracyclines,taxanes,Target:HER2 (ERBB2),taxanes,Congress:ASCO 2023, Search all connections
Abstract Incidence of hypomagnesemia in patients with HER2+ breast cancer treated with pertuzumab. Organization:University of Florid...,University of Florid...,Drug:pertuzumab,Trastuzumab,cetuximab,Target:HER2 (ERBB2),EGFR-TKI sensitizing..., Search all connections
Abstract A phase II study of weekly carboplatin and nab-paclitaxel with trastuzumab or bevacizumab as neoadjuvant therapy for patients with early-stage nonmetastatic breast cancer. Clinical trial:20076084,Organization:University of Califo...,UC Irvine Health,Chao Family Comprehe...,Drug:carboplatin, Search all connections
Abstract Decreased HER2 expression in residual disease following neoadjuvant therapy in patients with HER2-positive breast cancer. Organization:Yale-New Haven Healt...,Yale University Scho...,Drug:Trastuzumab,pertuzumab,ado trastuzumab emta...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Comparing time to treatment for neoadjuvant chemotherapy for breast cancer across the urban-rural continuum. Organization:Rush University Medi...,Drug:neoadjuvant chemothe...,Target:inflammatory breast ...,triple negative brea...,Estrogen Receptor (E...,Congress:ASCO 2023, Search all connections
Abstract Combined role of the neutrophil/lymphocyte ratio and Neo-Bioscore in neoadjuvant therapy in HER2-positive early breast cancer. Organization:Hospital Juan Ramón ...,Hospital Juan Ramon ...,Aodo Asociación Onub...,Drug:pertuzumab,Trastuzumab,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Efficacy and safety of neoadjuvant double anti-Her2 blockade combined with anthracycline-free chemotherapy in locally advanced breast cancer. Organization:Hospital Juan Ramón ...,Hospital Juan Ramon ...,Juan Ramón Jiménez H...,Drug:TCHP,Filgrastim,pegfilgrastim, Search all connections
Abstract Retrospective analysis of Ki-67 as a predictive and prognostic marker for pathological complete response to neoadjuvant chemotherapy in breast cancer. Organization:Tata Memorial Centre,BBCI (B Borooah Canc...,Dr Bhubaneswar Boroo...,Drug:Trastuzumab,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract INSIGHT-HER2BC: Real-world evidence of TCHP regimen to describe the best patient profile and open up questions—The interim results. Organization:Moscow Clinical Scie...,Moscow Oncology City...,SBIH Municipal Clini...,Drug:docetaxel,carboplatin,Trastuzumab, Search all connections
Abstract Neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancer: A pilot trial. Organization:Jiangsu Hengrui Phar...,Drug:pyrotinib,dalpiciclib,letrozole,Target:Estrogen Receptors (...,Cyclin-dependent kin...,EGFR-TKI sensitizing..., Search all connections
Abstract Racial disparity in the clinical outcomes of HER2-low and HER2-zero early-stage breast cancer. Organization:Roswell Park Compreh...,Buffalo, NY,Drug:neoadjuvant chemothe...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Neoadjuvant inetetamab combined with pertuzumab, paclitaxel, and carboplatin (TCbIP) for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study. Clinical trial:IPNCb-01,Organization:National Cancer Cent...,National Clinical Re...,Cancer Hospital, Chi...,Drug:Inetetamab,pertuzumab, Search all connections
Abstract Phase II neoadjuvant trial of albumin-bound paclitaxel, trastuzumab and pertuzumab followed by anthracycline based regimens in patients with operable HER2 positive breast cancer (OMC-BC05). Organization:Department of Breast...,Osaka Medical and Ph...,Department of Rehabi..., Search all connections
Abstract Role of plasma circulating HER2/EFTUD2 ratio in predicting pathological complete response (pCR) after neoadjuvant dual anti-HER2 therapy in HER2-positive breast cancer (HER2+ BC). Organization:Department of Clinic...,Department of Clinic...,Departments of Clini...,Drug:Trastuzumab,pertuzumab,taxane, Search all connections
Abstract Real-world, single-center experience on the outcomes of neoadjuvant chemotherapy and trastuzumab alone or in combination with pertuzumab in human epidermal growth factor receptor-2 breast cancer patients. Organization:Medanta Medicity,Medanta - The Medici...,Medanta- The Medicit...,Drug:Trastuzumab,pertuzumab,platinum-based chemo..., Search all connections
Abstract Reflex MammaPrint testing on breast core biopsies: A single center experience. Organization:University of Toront...,Odette Cancer Centre,Sunnybrook Health Sc...,Drug:MammaPrint,BluePrint,Target:HER2 (ERBB2),Hormone receptors, Search all connections
Abstract Defendor special: Interim analysis of TCHP with primary empegfilgrastim prophylaxis (long-acting G-CSF) for treatment outcomes in early HER2+ breast cancer. Organization:Moscow Clinical Scie...,Russian Cancer Resea...,Drug:docetaxel,carboplatin,Trastuzumab, Search all connections
Abstract Neoadjuvant therapy (NAT) in early breast cancer (EBC): Results from a prospective observational multicenter BRIDE study. Organization:Oncologia Medica - I...,IRCCS Regina Elena N...,Roma, Italy, Search all connections
Abstract A meta-analysis of cardiac toxicity of concurrent epirubicin and trastuzumab in early breast cancer. Organization:National Taiwan Univ...,Hsinchu City,Taiwan Bio Therapeut...,Drug:doxorubicin, Search all connections
Abstract Clinicopathological characteristics and outcome of very young breast cancer patients at a referral center in Iran. Organization:Shahid Beheshti Univ...,Shahid Beheshti Univ...,Drug:Luteinizing hormone-...,HER2 CAR-T,Target:HER2 (ERBB2),Luteinizing hormone-...,Congress:ASCO 2023, Search all connections
Abstract In search for new targets: Differences of HER2 receptor expression between CNB and synchronous axillary lymph node metastases in 205 patients. Organization:University of Leipzi...,Department of Gyneco...,Division of Breast S...,Drug:HER2 CAR-T,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Comprehensive genomic profiling of Taiwanese patients with breast cancer using a novel targeted panel: Preliminary analyses from a prospective triple-negative cohort. Organization:Taipei Veterans Gene...,Department of Pathol...,Drug:BRCA1,BRCA2,PALB2, Search all connections
Abstract Clinicopathologic features of early stage HER2-low breast cancer. Organization:Comprehensive Hemato...,St. Petersburg, FL,Drug:trastuzumab deruxtec...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Prevalence of low HER2 expression in breast cancer patients: An Indian experience. Organization:All India Institute ...,Department of Surgic...,Department of Radiat...,Drug:trastuzumab deruxtec...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract FcεRIγ-negative NK cells and association with improved outcomes in trastuzumab-treated patients. Organization:Tempus Labs, Inc.,Durham, NC,Statagize LLC, Search all connections
Abstract Lowering the bar for consideration of neoadjuvant chemotherapy in early-stage HER2-positive breast cancers. Organization:Henry Ford Cancer In...,Henry Ford Health Sy...,Drug:ado-trastuzumab emta...,TDM-1,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Subcutaneous versus endovenous trastuzumab: Real world data from a reference cancer center in Peru. Organization:Specialized Institut...,Instituto Nacional d...,Instituto Nacional d...,Drug:Trastuzumab,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Possible advantage of granulocyte colony-stimulating factor in breast cancer chemotherapy during COVID-19 pandemic: A single center experience in Japan. Organization:Nagoya Tokushukai Ge...,Drug:Filgrastim,peg-GCSF,ddAC, Search all connections
Abstract Evolution of breast cancer management in the Dominican Republic in the 21st century. Organization:FUNDEONCAP,IOHP,Dominican Society of...,Drug:Tamoxifen,aromatase inhibitors,pertuzumab, Search all connections
Abstract Cardiac safety of reduced surveillance for cancer therapy related cardiac dysfunction in patients with breast cancer treated with HER2-targeted therapy. Organization:Memorial Sloan Kette...,Hartford Healthcare ...,Hartford Healthcare ...,Drug:Tiragolumab,Trastuzumab,pertuzumab, Search all connections
Abstract Cardiac dysfunction (CD) among breast cancer survivors (BCS): Role of cardiotoxic therapy and cardiovascular risk factors. Organization:University of Alabam...,University of Alabam...,University of Alabam...,Drug:anthracyclines, Search all connections
Abstract PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A Children’s Oncology Group Pediatric Early-Phase Clinical Trial Network study. Clinical trial:NCI-2020-08428,Organization:H. Lee Moffitt Cance...,Dana-Farber Cancer I...,Institute for Clinic..., Search all connections
Abstract Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction (PCR) versus next-generation sequencing (NGS) testing strategies in metastatic non-small cell lung cancer (mNSCLC). Organization:University of Chicag...,Janssen Scientific A...,Analysis Group, Inc.,Drug:EGFR-tyrosine kinase...,Melphalan,ROS1 TKIs, Search all connections
Abstract Association of Medicaid expansion with timely receipt of treatment and survival among patients with HER2-enriched breast cancer. Organization:American Cancer Soci...,Atlanta Cancer Care,Galderma R&D, Search all connections
Abstract Racial disparities in utilization of first line targeted therapies for metastatic breast cancer. Organization:University of Pennsy...,Department of Medici...,Perelman School of M...,Drug:CDK4/6 inhibitors,pertuzumab,Target:HER2 (ERBB2),CDK6,CDK4 & 6, Search all connections
Abstract A master screening study to determine biomarker status and trial eligibility for patients with malignant tumors. Organization:Peter MacCallum Canc...,Roche Products Ltd.,F. Hoffmann-La Roche...,Drug:EGFR-tyrosine kinase...,Melphalan,ROS1 TKIs, Search all connections
Abstract Anti-tumor activity of sunvozertinib in NSCLC with EGFR sensitizing mutations after failure of EGFR TKI treatment. Clinical trial:DZ2021E0006,Organization:Department of Respir...,Chi Mei Chest Hospit...,Department of Oncolo..., Search all connections
Abstract Safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with non-small cell lung cancer (NSCLC): An open-label, phase Ib trial. Organization:Department of Medica...,Sun Yat-sen Universi...,State Key Laboratory..., Search all connections
Abstract A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY). Organization:National Cancer Cent...,Department of Thorac...,Osaka International ..., Search all connections
Abstract Survival associations and driver oncogene overlap for copy-number amplifications of ERBB2, KRAS and MET in non-small cell lung cancer. Organization:Tom Baker Cancer Cen...,Calgary, AB, Canada,Caris Life Sciences,..., Search all connections
Abstract Spectrum of acquired KRAS mutations in driver mutation-positive non-small cell lung cancer. Organization:Caris Life Sciences,...,West Virginia Univer...,Mayo Clinic,Drug:KRAS G12C,KRAS G12V,Kras G12Di, Search all connections
Abstract Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2-mutant non-small cell lung cancer (NSCLC). Organization:Memorial Sloan Kette...,Resolution Bioscienc...,Agilent,Drug:trastuzumab deruxtec...,pembrolizumab,trastuzumab-emtansin...,Target:HER2 (ERBB2),PD-1, Search all connections
Abstract Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting. Organization:EMD Serono Research ...,Genesis Research,Thoracic Oncology Se...,Drug:EGFR-tyrosine kinase...,KRAS,Melphalan, Search all connections
Abstract Effects of mutations in SWI/SNF subunits on context-specific prognosis in driver positive and driver negative NSCLC. Organization:Caris Life Sciences ...,Caris Life Sciences,...,Lombardi Comprehensi...,Drug:KRAS,EGFR-tyrosine kinase...,BRAF, Search all connections
Abstract The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP. Organization:Mount Sinai Health S...,SWOG Statistics and ...,Fred Hutchinson Canc..., Search all connections
Abstract Analytical and clinical validation of Oncomine Dx Target (ODxT) test and local testing for identifying patients with HER2 (ERBB2)-mutant (HER2m) non–small-cell lung cancer (NSCLC) for treatment with trastuzumab deruxtecan (T-DXd) in DESTINY-Lung01/02 (DL-01/02). Organization:Memorial Sloan Kette...,New York, NY,Netherlands Cancer I..., Search all connections
Abstract Real-world testing and treatment patterns among patients with stage IV non-small cell lung cancer: A retrospective observational study. Organization:Integra Connect Prec...,Massachusetts Genera...,Sarah Cannon Researc...,Drug:TKI, Search all connections
Abstract Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data. Clinical trial:1479-0001,Organization:MD Anderson Cancer C...,Department of Clinic...,The Netherlands Canc..., Search all connections
Abstract Retrospective analysis of genetically matched therapies in salivary gland cancer entities using a real-world database in a tertiary salivary gland cancer expertise center. Organization:Department of Medica...,Department for Healt...,Department of Urolog...,Drug:ERBB2 targeting agen...,monoclonal antibodie...,tyrosine kinase inhi..., Search all connections
Abstract Personalized therapy for head and neck squamous carcinoma (HNSCC) utilizing tissue proteomics profiling. Organization:mProbe Inc.,Stanford University ...,Drug:mFOLFOXIRI,topotecan,doxorubicin, Search all connections
Abstract Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway: Results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM). Clinical trial:EORTC-1559-HNCG,Organization:Cliniques Universita...,Department of Drug D...,Institut Curie, Sain..., Search all connections
Abstract AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer. Clinical trial:AFT-50,Organization:Alliance Statistics ...,Mayo Clinic,Rochester, MN, Search all connections
Abstract TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum. Clinical trial:GINECO-OV244b,Organization:Gustave-Roussy Cance...,Institut Claudius Re...,IUCT-Oncopole Toulou..., Search all connections
Abstract Correlation of cardiovascular disease with racial disparities in endometrial cancer outcomes. Organization:Medical College of W...,Froedtert and the Me...,Drug:lenvatinib,Trastuzumab,Target:HER2 (ERBB2),Lenvatinib (L),Congress:ASCO 2023, Search all connections
Abstract Distinguishing primary mucinous ovarian tumors from metastases of non-gynecologic mucinous cancers: Can we leverage next-generation sequencing? Organization:Weill Cornell Medici...,Doha, Qatar,Qatar,Drug:CDKN2A/B, Search all connections
Abstract Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study. Organization:University of Califo...,Helen Diller Family ...,University of Califo..., Search all connections
Abstract Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b/2 study. Organization:Peking University Ca...,Peking University Fi...,Affiliated Drum Towe..., Search all connections
Abstract Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program. Organization:Garvan Institute of ...,The Kinghorn Cancer ...,Chris O'Brien Lifeho..., Search all connections
Abstract Trastuzumab (T) plus gemcitabine-cisplatin (GC) for treatment naïve HER2 positive biliary tract adenocarcinomas (BTC): A multicentre open-label, phase II study (TAB). Organization:Tata Memorial Hospit...,Tata Memorial Centre,Homi Bhabha cancer h...,Drug:FF-10832,Cisplatin,Trastuzumab,Target:TERT, Search all connections
Abstract A novel patient-centric longitudinal data registry platform to generate insights into real-world cholangiocarcinoma (CCA) clinical practice. Organization:Invitae,The University of Te...,Mayo Clinic Arizona,...,Drug:IDH1 R132,FGFR2 Fusion / Rearr..., Search all connections
Abstract Advancing individualized care in advanced gastroesophageal cancers (GEC): A quality improvement initiative. Organization:Massachusetts Genera...,PRIME Education LLC,Drug:HER2 CAR-T,EGFR-tyrosine kinase...,FGFRi,Target:EGFR-TKI sensitizing..., Search all connections
Abstract Final survival results of ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive esophago gastric adenocarcinoma: The randomized AIO INTEGA trial. Organization:University Cancer Ce...,University Medical C...,Hämatologisch-Onkolo..., Search all connections
Abstract MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer. Clinical trial:SGNTUC-017,Organization:Mayo Clinic,University Hospitals...,KU Leuven, Search all connections
Abstract Efficacy and safety of KN026 in combination with KN046 in patients with locally advanced unresectable or metastatic HER2-positive other solid tumors. Organization:Beijing Cancer Hospi...,Cancer Hospital of S...,Central Hospital Aff..., Search all connections
Abstract Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial. Organization:Department of Oncolo...,Department of Oncolo...,Division of Patholog..., Search all connections
Abstract HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS. Clinical trial:SGNTUC-017,Organization:Duke University Medi...,Division of Solid Tu...,Memorial Sloan Kette..., Search all connections
Abstract A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors. Organization:Department of Invest...,The University of Te...,Houston, TX, Search all connections
Abstract Impact of HER2 assay sensitivity on the ability to detect tumors with low to ultra-low HER2 expression: A TMA study on more than 10,000 tumors from more than 100 tumor entities. Organization:University Medical C...,Institute of Patholo...,Academic Hospital Fu...,Drug:HercepTest,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Evolution of HER2 scores after neoadjuvant systemic therapy in breast cancer. Organization:Loma Linda Universit...,Loma Linda Universit...,Division of Medical ...,Drug:antibody-drug conjug...,Target:HER2 (ERBB2), Search all connections
Abstract Exploring expression levels of HER2, HER3, MET, Claudin18.2, and MUC16 across 16 cancer types using an artificial intelligence-powered immunohistochemistry analyzer. Organization:Oncology Therapeutic...,Lunit Inc.,Samsung Medical Cent...,Drug:Muc16CD,CLDN18.2, Search all connections
Abstract NRG1 fusions in solid tumors. Organization:Caris Life Sciences,...,Caris Life Sciences ...,West Cancer Center a...,Drug:zenocutuzumab,Target:HER2 (ERBB2),HER3,NRG1,Congress:ASCO 2023, Search all connections
Abstract Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy. Organization:NHMRC Clinical Trial...,The University of Sy...,Sydney, NSW, Austral..., Search all connections
Abstract Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC). Organization:Illumina, Inc.,Drug:EGFR-tyrosine kinase...,BRAF,KRAS,Product:TMZ, Search all connections
Abstract FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study. Clinical trial:FS-CY1502-Ph1-01,Organization:Beijing Fosun Pharma...,Shanghai Fosun Pharm...,Fosun Pharma USA, In...,Drug:FS-1502,Trastuzumab,pertuzumab, Search all connections
Abstract A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors. Clinical trial:BB-1701-101,Organization:Cancer Hospital of C...,Chinese Academy of M...,Beijing, China, Search all connections
Abstract Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers. Clinical trial:15-335,Organization:Memorial Sloan Kette...,Weill Cornell Medica...,Drug:Ado-Trastuzumab emta...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study. Clinical trial:DB-1303-O-1001,Organization:Stephenson Cancer Ce...,Macquarie University...,Phase I Clinical Tri..., Search all connections
Abstract A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors. Organization:City of Hope Compreh...,University of Texas ...,The Sarah Cannon Res..., Search all connections
Abstract A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors. Clinical trial:BBI-20201001,Organization:Memorial Sloan Kette...,Stanford University ...,Seoul National Unive..., Search all connections
Abstract HER2-low breast cancer brain metastases: Incidence and treatment implications. Organization:University of Toront...,Sunnybrook Hospital,Toronto, ON, Canada,Drug:trastuzumab deruxtec..., Search all connections
Abstract A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases. Organization:Université de Montré...,McGill University He...,Department of Medica..., Search all connections
Abstract Progress report of a cross-organ and biomarker-based platform study: BELIEVE trial NCCH1901. Organization:National Cancer Cent...,Chuo-Ku, Japan,Department of Labora...,Drug:BRAF, Search all connections
Abstract Use and value of self-management (SM) recommendations in a real-world evidence study evaluating digital patient monitoring (DPM) of patients (pts) receiving cancer care. Organization:University of Lausan...,School of Health Sci...,University of Applie...,Drug:non-small/small cell...,HER2-positive breast...,Target:HER2 (ERBB2), Search all connections
Abstract Korean Precision Medicine Networking Group study of molecular profiling guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) II (KCSG AL 22-09). Clinical trial:KCSG AL 22-09,Organization:Department of Oncolo...,Department of Intern...,Seoul National Unive..., Search all connections
Abstract System-wide approach on biosimilars adoption in oncology: Strategic plan on switching and cost savings. Organization:Cedars-Sinai Medical...,Cedars-Sinai Medical...,Cedars-Sinai Cancer,Drug:bevacizumab,Varlilumab, Search all connections
Abstract Correlation between Oncotype DX, Predict, and Nottingham Prognostic Index on HR+, HER2- early breast cancer treatment: The current value of molecular testing. Organization:University of Miami ...,Ecua-american Labora...,Hospital de los Vall...,Drug:ODX,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer. Organization:Stanford Hospital & ...,Department of Manage...,Stanford University ...,Drug:trastuzumab deruxtec...,physician's choice c...,trastuzumab-deruxtec...,Target:HER2 (ERBB2), Search all connections
Abstract Can synthetic data accurately mimic oncology clinical trials? Organization:CHEO Research Instit...,Replica Analytics,Ottawa Hospital Rese...,Drug:REaCT-G_G2, Search all connections
Abstract Implementation of a streamlined prior authorization process to improve cancer care delivery. Organization:Division of Hematolo...,Drug:lanreotide,feraheme,nivolumab,Target:HER2 (ERBB2),PD-1,Somatostatin Recepto..., Search all connections
Abstract Impact of geography on receipt of medical oncology consultation and neoadjuvant chemotherapy for triple negative and HER2 positive breast cancer. Organization:University of Toront...,Odette Cancer Centre,Sunnybrook Health Sc...,Drug:neoadjuvant chemothe...,placebo,Target:HER2 (ERBB2), Search all connections
Abstract The impact of the 4R Oncology model of team-based care delivery on timing and sequence of guideline recommended interdependent care in breast and lung cancers. Organization:Center for Business ...,Genentech Inc, South...,Albert Einstein Coll...,Drug:endocrine therapy,HER2+,Target:HER2 (ERBB2),Estrogen Receptor (E..., Search all connections
Abstract Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial. Clinical trial:IIT2018-04-MCARTHUR-...,Organization:University of Texas ...,Clion - CAM Group,Cedars-Sinai Medical..., Search all connections
Abstract Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial). Organization:Department of Surger...,Seoul National Unive...,Department of Radiol..., Search all connections
Abstract A phase II study of concurrent WOKVAC vaccination with neoadjuvant chemotherapy and HER2-targeted monoclonal antibody therapy. Clinical trial:RG1005296,Organization:University of Washin...,Cancer Vaccine Insti...,University of Washin...,Drug:Trastuzumab,pertuzumab,WOKVAC,Target:HER2 (ERBB2), Search all connections
Abstract Selective avoidance of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with HER-2 positive/triple negative breast cancer: Prospective, multi-center, single-arm study (ASLAN). Organization:Division of Breast S...,Department of Surger...,Department of Surger..., Search all connections
Abstract SMALL: Open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer—A UK phase III randomised multi-centre trial. Organization:Queen's University B...,University of Cambri...,University of Oxford, Search all connections
Abstract NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer. Clinical trial:NRG-BR007,Organization:University of Kansas...,NRG Oncology SDMC,The University of Pi..., Search all connections
Abstract A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD). Organization:Division of Medical ...,Department of Medici...,Princess Margaret Ca..., Search all connections
Abstract Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neoadjuvant and postoperative adjuvant anti-HER2 therapy: Flamingo-01. Clinical trial:GLSI-21-01,Organization:Greenwich LifeScienc...,Stafford, TX,Lester and Sue Smith...,Drug:GP2, Search all connections
Abstract HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer. Clinical trial:SGNTUC-028,Organization:Sarah Cannon Researc...,Hospital General Uni...,Mayo Clinic, Search all connections
Abstract A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors. Organization:Sarah Cannon Researc...,Tennessee Oncology, ...,NEXT Oncology - Virg..., Search all connections
Abstract Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL. Clinical trial:097517,Organization:University of Califo...,Wake Forest Universi...,University of Califo..., Search all connections
Abstract Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC). Clinical trial:MCC-21378,Organization:H. Lee Moffitt Cance...,Vaccinex, Inc.,Drug:Trastuzumab,pepinemab,Target:HER2 (ERBB2),SEMA4D,Congress:ASCO 2023, Search all connections
Abstract The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab. Organization:Nottingham Univ City...,Van Geest Cancer res...,School of Science an..., Search all connections
Abstract Whole-genome sequencing based assessment of HER2 focal amplification for precision oncology of breast cancers. Organization:Genome Insight Inc.,Samsung Medical Cent...,Division of Breast S...,Drug:docetaxel, Search all connections
Abstract Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer. Clinical trial:I-19-04120,Organization:Roswell Park Compreh...,Buffalo, IL,Nykode Therapeutics, Search all connections
Abstract Moderate physical exercise and immune system modulation in patients with breast cancer treated with neoadjuvant chemotherapy. Organization:Medical Oncology Fon...,Laboratorio di Oncol...,Medical Oncology, AO...,Drug:epirubicin,cyclophosphamide,Tiragolumab, Search all connections
Abstract Association of HER2/CEP17 ratio with pCR after HER2-directed neoadjuvant treatments in the phase III NeoALTTO trial. Organization:Comprehensive Cancer...,Medical University o...,Dept of OB/GYN, Karl..., Search all connections
Abstract Neoadjuvant giredestrant + palbociclib (P) vs. anastrozole (A) + P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+, HER2– eBC): Patient (pt)-reported outcomes (PROs) in the randomized, open-label, international phase II coopERA BC study. Clinical trial:WO42133,Organization:Samsung Medical Cent...,GEICAM Spanish Breas...,University Hospital ..., Search all connections
Abstract Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab. Organization:Memorial Sloan Kette...,Drug:trastuzumab emtansin...,trastuzumab deruxtec...,pertuzumab,Target:HER2 (ERBB2),tubulin, Search all connections
Abstract Neoadjuvant therapy of HER2 directed conventional dendritic cell (DC1) intratumoral (IT) therapy plus weekly paclitaxel, trastuzumab, and pertuzumab in patients with HER-2 positive breast cancer: NATASHA trial. Clinical trial:MCC-20915,Organization:H. Lee Moffitt Cance...,H. Lee Moffit Cancer...,Drug:IT DC1,Trastuzumab,pertuzumab,Target:HER2 (ERBB2), Search all connections
Abstract Treatment outcomes in patients with discordant recurrence score and RSClin risk predictions. Organization:University of Chicag...,University of Chicag...,University of Chicag...,Drug:Cisplatin,adjuvant chemotherap...,Androgen deprivation..., Search all connections
Abstract Outcomes in premenopausal patients with HR+/HER2- breast cancer and lymph node micro-metastasis based on the 21-gene recurrence score. Organization:Icahn School of Medi...,Icahn School of Medi...,Drug:chemoendocrine thera...,endocrine monotherap...,Target:HER2 (ERBB2),Hormone receptor pos...,Hormone receptors,Congress:ASCO 2023, Search all connections
Abstract ERBB2 mRNA expression to distinguish HER2-low/neg breast cancer prognosis. Organization:The Fourth Hospital ...,Fudan University Sha...,Shanghai Medical Col...,Drug:trastuzumab deruxtec...,Target:HER2 (ERBB2), Search all connections
Abstract Impact of HER2 low expression in the Oncotype DX RS in patients with operable hormone receptor positive early stage breast cancer. Organization:Weill Cornell Medici...,New York Oncology He...,Weill Cornell Medici...,Drug:Oncotype DX RS,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Association of human epidermal growth factor receptor 2 expression with 21-gene recurrence score and survival among patients with estrogen receptor–positive breast cancer. Organization:Roswell Park Compreh...,University at Buffal...,Department of Radiat...,Drug:trastuzumab-deruxtec...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Impact of race on BluePrint genomic subtyping in HER2+ breast cancer. Organization:Vanderbilt-Ingram Ca...,Vanderbilt Universit...,Division of Epidemio..., Search all connections
Abstract Decision value of the circulating tumor DNA on the adjuvant anti-Her2 regimens in patients with Her2-positive breast cancer treated with neoadjuvant therapy. Organization:National Taiwan Univ...,National Taiwan Univ...,Drug:T-DM1,Trastuzumab,pertuzumab,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Trends and outcomes of systemic therapy in hormone receptor-positive early-stage male breast cancer: A propensity score analysis. Organization:Department of Breast...,Nosocomial Infection...,Department of Breast...,Drug:endocrine therapy,Cisplatin, Search all connections
Abstract Cardiac safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin (PLD) or doxorubicin. Organization:Fudan University Sha...,Cancer Institute of ...,Shanghai Medical Col..., Search all connections
Abstract Additional prognostic value of the BCT score in patients with ER+HER2- breast cancer receiving 21-gene assay–guided adjuvant treatments. Organization:Gangnam Severance Ho...,Yonesi University Co...,Seoul National Unive..., Search all connections
Abstract Disease-free survival (DFS) as a surrogate for overall survival (OS) in patients (pts) with HR+/HER2− early breast cancer (EBC): A correlation analysis. Organization:Helios Klinikum Berl...,Dana-Farber Cancer I...,International Breast..., Search all connections
Abstract The worldwide impact of HER2-targeted treatments in women with breast cancer: An epidemiological modeling study. Organization:Genentech Inc.,F. Hoffmann-La Roche...,Drug:Trastuzumab,pertuzumab,T-DM1,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Distribution and outcomes of HER2-low and HER2-zero metastatic breast cancer in Black and younger women. Organization:UNC Lineberger Compr...,University of North ...,Department of Medici...,Drug:CDK4/6i,etoposide,Cisplatin, Search all connections
Abstract A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2–positive breast cancer. Clinical trial:MCC-19117,Organization:H. Lee Moffitt Cance...,Ohio State Universit...,Indiana University S..., Search all connections
Abstract Association of pretreatment chest CT abnormalities with trastuzumab deruxtecan–associated pneumonitis. Organization:Massachusetts Genera...,Harvard Medical Scho...,Division of Thoracic...,Drug:trastuzumab deruxtec...,trastuzumab-deruxtec...,Target:HER2 (ERBB2), Search all connections
Abstract Real-world (RW) outcomes of patients (pts) with advanced breast cancer (aBC) with and without resistance alterations (alts) detected in cell-free circulating tumor DNA (ctDNA) prior to CDK4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) treatment. Organization:Massachusetts Genera...,Harvard Medical Scho...,Guardant Health, Inc..., Search all connections
Abstract Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer. Clinical trial:eFT226-0002,Organization:Memorial Sloan Kette...,START Midwest, Grand...,Valkyrie Clinical Tr..., Search all connections
Abstract A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i). Clinical trial:STUDY00000057,Organization:Medstar Georgetown U...,Department of Biosta...,Dana-Farber Cancer I...,Drug:bosutinib, Search all connections
Abstract Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial. Clinical trial:CLEE011A3201C,Organization:American University ...,National Cancer Cent...,Acıbadem Research In..., Search all connections
Abstract ctDNA mutational profiles in luminal breast cancer with early vs late distant relapse: Geicam/2014-03. Organization:Fundación Instituto ...,GEICAM Spanish Breas...,Hospital Universitar..., Search all connections
Abstract Metastatic patterns and outcomes by HER2 and hormone receptor (HR) status in patients (pts) with metastatic breast cancer (mBC). Organization:Flatiron Health, San...,Drug:trastuzumab deruxuta...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Prognostic factors in hormone receptor positive oligometastatic breast cancer. Organization:Institut Claudius Re...,Institut Universitai...,Département d’Oncolo..., Search all connections
Abstract Validation of a single-cell sequencing assay for the detection of circulating tumor cells in metastatic breast cancer. Organization:Epic Sciences, Inc.,Drug:Erwinia asparaginase,HER2 CAR-T,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Real-world patient characteristics and treatment patterns associated with tucatinib therapy in patients with HER2+ metastatic breast cancer. Organization:Duke University Canc...,Seagen, Inc.,Genesis Research,Drug:Tucatinib,Trastuzumab,CAPOX, Search all connections
Abstract HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers. Organization:Memorial Sloan Kette...,Memorial Sloan Kette...,Lombardi Comprehensi...,Target:HER2 (ERBB2),Drug:trastuzumab-deruxtec...,Congress:ASCO 2023, Search all connections
Abstract Real-world treatment patterns in patients with HER2+ unresectable or metastatic breast cancer: Interim results from HER2 REAL Asia cohort. Organization:National University ...,National Cheng Kung ...,Queen Elizabeth Hosp...,Drug:trastuzumab emtansin..., Search all connections
Abstract First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors. Clinical trial:C4551001,Organization:Next Oncology Virgin...,Sarah Cannon Researc...,Tennessee Oncology, ..., Search all connections
Abstract PLEASURABLE: Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC). Organization:Fudan University Sha...,Department of Breast...,Hubei Cancer Hospita..., Search all connections
Abstract Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer: Final results from the phase 2 ICU trial. Organization:Department of Breast...,Henan Breast Cancer ...,The Affiliated Cance..., Search all connections
Abstract Preclinical and early clinical data of ZN-1041 in combination with trastuzumab deruxtecan to treat breast cancer with or without CNS metastases. Organization:Duke Cancer Institut...,Dana-Farber Cancer I...,The Oncology Institu...,Drug:ZN-1041,trastuzumab emtansin...,TDM1, Search all connections
Abstract Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases. Clinical trial:ZN-A-1041-101-US,Organization:National Cancer Cent...,Cancer Institute and...,Sun Yat-sen Memorial..., Search all connections
Abstract Updated results from a phase 2 study on dalpiciclib and pyrotinib, a dual-oral chemotherapy-free regimen in HER2-positive advanced breast cancer (DAP-HER-01). Organization:Department of Breast...,Henan Breast Cancer ...,Jiangsu Hengrui Phar...,Drug:dalpiciclib,pyrotinib,Target:CDK4/6,HER2 (ERBB2), Search all connections
Abstract Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial. Clinical trial:HR-MBC-HN001,Organization:Department of Breast...,The Affiliated Cance...,Department of Breast..., Search all connections
Abstract Cardiac function of long-responders to dual anti-HER2 antibodies amongst patients with HER2 positive advanced breast cancer. Organization:Department of Clinic...,Queen Elizabeth Hosp...,Hong Kong Sanatorium...,Drug:pertuzumab,Trastuzumab,taxane,Target:HER2 (ERBB2),taxanes, Search all connections
Abstract Gene expression profiling of paired primary breast cancers and brain metastases to identify brain metastases-specific biological changes. Organization:University of Padua ...,Division of Medical ...,Montefiore Medical C..., Search all connections
Abstract Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study. Clinical trial:BGB-A317-ZW25-101,Organization:BeiGene (Shanghai) C...,The Fifth Medical Ce...,Drug:zanidatamab,ZW25,docetaxel,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Comprehensive characterization of androgen receptor expression in breast cancer. Organization:Caris Life Sciences,...,City of Hope Nationa...,Washington Universit...,Drug:doxorubicin,Tiragolumab,Trastuzumab,Target:FOXP3, Search all connections
Abstract Association of C-MYC, MYC target gene, and unfolded protein response (UPR) expression with clinical benefit from the oral aurora kinase A (AURKA) inhibitor, alisertib (A), in combination with paclitaxel (P) compared with P alone in patients (Pts) with HER2-negative metastatic breast cancer (MBC). Organization:Integrated Cancer Ge...,Translational Genomi...,Phoenix, AZ, Search all connections
Abstract Clinical features, genomic landscapes, and survival outcomes of HER2-low breast cancer. Organization:Fudan University (Xi...,Shanghai Cancer Cent...,Shanghai Medical Col...,Drug:trastuzumab deruxtec...,adotrastuzumab emtan...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Biosimilar uptake and cost savings analysis before and after implementation of a pharmacist-driven substitution program within a National Community Oncology Network: One-year follow-up. Organization:American Oncology Ne...,Fort Myers, FL,Drug:bevacizumab,Trastuzumab,Varlilumab,Target:pegfilgrastim, Search all connections
Abstract LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer. Organization:NeoGenomics Ltd, Cam...,Medipole Lyon Villeu...,Infirmerie Protestan...,Drug:EGFR-tyrosine kinase...,BRAF V600E,Melphalan, Search all connections
Abstract Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogene-driven resectable non-small cell lung cancer (NSCLC). Clinical trial:J1414,Organization:Johns Hopkins Univer...,Johns Hopkins Sidney...,Sidney Kimmel Compre..., Search all connections
Abstract Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806). Organization:Guardant Health, Inc...,Department of Molecu...,Department of Biosta...,Target:HER2 (ERBB2),Drug:trastuzumab-deruxtec...,Congress:ASCO 2023, Search all connections
Abstract A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors. Clinical trial:TAC01-HER2-03,Organization:DFCI/BWH Cancer Cent...,University of Chicag...,Comprehensive Cancer..., Search all connections
Abstract Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL. Clinical trial:097517,Organization:Mayo Clinic,University of Alabam...,University of Roches..., Search all connections
Abstract Axillary surgery efficacy for patients with breast cancer receiving neoadjuvant chemotherapy on NSABP B40 and B41. Organization:University of Florid...,University of Florid...,Francis H. Burr Prot...,Drug:neoadjuvant chemothe...,Target:HER2 (ERBB2),Estrogen Receptor (E...,progesterone recepto..., Search all connections
Abstract Outcomes according to treatment received for small node-negative HER2+ breast tumors in the Surveillance, Epidemiology, and End Results (SEER) database, 2010-2019. Organization:Dana-Farber Cancer I...,Unidad Oncologica de...,Cooperative Oncologi...,Drug:Cisplatin,Target:HER2 (ERBB2),Congress:ASCO 2023,ASCO 2019, Search all connections
Abstract Gene expression signatures, stromal tumor infiltrating lymphocytes (sTILs), and change in tumor cellularity to predict pathological complete response (pCR) after 12 week de-escalated neoadjuvant endocrine therapy (ET) vs paclitaxel + dual HER2 blockade in the WSG-TP-II trial. Organization:West German Study Gr...,Moenchengladbach, Ge...,Klinikum Dortmund gG...,Clinical trial:PH002-TP-II,Drug:Tiragolumab,Trastuzumab,pertuzumab, Search all connections
Abstract MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST. Organization:Dallas Surgical Grou...,Bon Secours Cancer I...,Yale University, Search all connections
Abstract Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study. Organization:Institut de Cancerol...,Gustave Roussy Cance...,ICO Institut de Canc..., Search all connections
Abstract Metabolic changes due to dexamethasone premedication in patients with breast cancer. Drug:dexamethasone,doxorubicin,cyclophosphamide,Target:cyclophosphamide,Topoisomerase II,beta-tubulin, Search all connections
Abstract Effect of fructose on anthracycline and HER-2 blocking agent mediated cardiotoxicity through NLRP3 and MyD88 mediated pathways: New roles of sweeteners in cardio-oncology. Drug:anthracyclines,HER-2 blocking agent...,doxorubicin,Target:IL-12,4-HNA,NLRP-3, Search all connections
Abstract A phase 2, single arm, European multi-center trial evaluating the efficacy of afatinib as first line or later line treatment in advanced chordoma. Drug:afatinib,Target:EGFR-TKI sensitizing...,HER2 (ERBB2),Organization:Leiden, Netherlands,250 Euston Road,Chordoma Foundation,Congress:ASCO 2024, Search all connections
Abstract The frequency of HER2-low breast cancer among BRCA1, BRCA2, and PALB2 mutation carriers. Organization:Hospital of Universi...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Clinical significance of HER2 expression between primary tumors and metastatic lymph nodes in patients with extramammary Paget's disease. Drug:Disitamab Vedotin (R...,Organization:Sun Yat-sen Universi...,State Key Laboratory...,Collaborative Innova..., Search all connections
Abstract Exposure-response (ER) analyses of efficacy and safety of trastuzumab deruxtecan (T-DXd) to inform dosing recommendation in HER2-mutant non-small cell lung cancer (NSCLC). Organization:Syndax Pharmaceutica...,Target:HER2 (ERBB2),Clinical trial:DS8201-A-U204,Drug:trastuzumab-deruxtec...,Congress:ASCO 2024, Search all connections
Abstract Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC). Drug:deruxtecan,trastuzumab-deruxtec...,Organization:Syndax Pharmaceutial...,Tariffville, CT,Target:HER2 (ERBB2),Clinical trial:DS8201-A-U206,Congress:ASCO 2024, Search all connections
Abstract Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data. Drug:zongertinib,Organization:Mary Crowley Cancer ...,Guangdong Lung Cance...,Valkyrie Clinical Tr...,Target:HER2 (ERBB2), Search all connections
Abstract A phase II umbrella clinical trial of advanced salivary gland cancer based on molecular typing. Drug:SHR-A1811,rezvilutamide,leuprolide,Target:TROP2,androgen-receptor (A...,HER2 (ERBB2),Organization:Minimally Invasive T..., Search all connections
Abstract Multiomic analysis in ovarian clear cell carcinoma to gain insight into biology and therapeutic opportunities. Drug:trastuzumab deruxtec...,Organization:Portland,OR,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract The tumor immune profile of bladder cancer (BC) with HER2 over-expression and the investigation into RC48-ADC versus BCG in high-risk non-muscle invasive BC with HER2 over-expression. Drug:bacillus Calmette-Gu...,Disitamab vedotin,RC48-ADC,Target:innate immunity,adaptive immunity,Organization:Department of Urolog...,Institute of Urology, Search all connections
Abstract Preliminary results from a phase II study to evaluate the efficacy and safety of perioperative disitamab vedotin (RC48-ADC) plus cadonilimab (AK104, PD-1/CTLA-4 bispecific antibody) for HER2-expressing muscle-invasive bladder cancer (MIBC). Drug:Cisplatin,RC48-ADC,PD-1/CTLA-4 antibody,Target:CTLA-4,PD-1,Organization:Department of Urolog..., Search all connections
Abstract Preliminary results from a multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03). Drug:RC48-ADC,tislelizumab,Target:PD-1,HER2 (ERBB2),Organization:West China Hospital,Sichuan University,Department of Urolog..., Search all connections
Abstract Efficacy and safety of neoadjuvant therapy with disitamab vedotin plus toripalimab in treating muscle invasive urothelial bladder cancer followed by selective bladder-preserving or radical cystectomy. Drug:Cisplatin,Disitamab vedotin,toripalimab,Target:PD-1,DNA,Organization:Department of Urolog...,Xiangya Hospital of ...,Central South Univer..., Search all connections
Abstract Disitamab vedotin (DV, RC48-ADC) combined with cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): An open-label, single-arm, phase II study. Drug:RC48-ADC,Cadonilimab,Target:CTLA-4,PD-1,HER2 (ERBB2),Organization:Cancer Hospital Affi...,General Internal Med...,Clinical trial:AK104-RC48 UC 01, Search all connections
Abstract Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study. Drug:Disitamab vedotin,RC48,camrelizumab,Target:PD-1,Organization:Department of Gastro...,Shandong Cancer Hosp...,Shandong First Medic..., Search all connections
Abstract Influence of neoadjuvant regimen on the prognosis of locally advanced gastric and gastroesophageal junction cancer with HER2 overexpression. Drug:anti-PD-1 immunother...,anti-HER2 agents,Target:PD-1,HER2 (ERBB2),Organization:Cancer Hospital Affi...,Henan Cancer Hosptal,Congress:ASCO 2024, Search all connections
Abstract Triple combination treatment of trastuzumab, chemotherapy and immune checkpoint inhibitor in HER2 positive unresectable, locally advanced, metastatic gastric and esophageal adenocarcinoma: A systematic review and meta-analysis. Drug:Trastuzumab,Organization:Quezon City,Philippines,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Immune checkpoint inhibitor plus chemotherapy versus chemotherapy alone in HER2-negative advanced gastric or gastroesophageal junction cancer: A systematic review and meta-analysis of randomized controlled trials. Drug:immune checkpoint in...,PD-1 inhibitors,PD-L1 inhibitors,Target:PD-1,PD-L1,Organization:Federal Univerity of...,DASA Oncologia, Search all connections
Abstract Efficacy and safety of SOX regimen combined with inetetamab as first-line treatment for HER2-positive advanced gastric cancer. Drug:Inetetamab,Trastuzumab,Organization:The Second Affiliate...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER). Drug:Tucatinib,Trastuzumab,Organization:Keck Medical Center ...,Target:HER2 (ERBB2),Clinical trial:SGNTUC-017,Congress:ASCO 2024, Search all connections
Abstract Peony exploratory analyses of biomarker changes: From baseline to surgical samples in patients with HER2+ breast cancer. Drug:pertuzumab,Trastuzumab,docetaxel,Organization:Roche (China) Holdin...,Product Development ...,Target:HER2 (ERBB2),Clinical trial:YO28762,Congress:ASCO 2024, Search all connections
Abstract HER2 expression-independent antitumor effect of trastuzumab deruxtecan (T-DXd) on pediatric solid tumors. Drug:trastuzumab deruxtec...,DXd,Organization:Division of Cancer I...,Children's Cancer Ce...,National Center for ...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract FS-1502 in patients with HER2 high expression, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: An open-label, multicenter, phase II study. Drug:FS-1502,Monomethylauristatin...,Organization:Meizhou People's Hos...,Meizhou Academy of M...,Meizhou Hospital Aff...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Phase 1 study of ZV0203, a first in class pertuzumab ADC, in patients with HER2 positive advanced solid tumors. Drug:ZV0203,DUO5,Trastuzumab,Target:tubulin,HER2 (ERBB2),Organization:Hangzhou Adcoris Bio..., Search all connections
Abstract Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm study. Drug:Disitamab vedotin,fruquintinib,Organization:Department of Abdomi...,Target:HER2 (ERBB2),Clinical trial:HCCSC C03,Congress:ASCO 2024, Search all connections
Abstract Association between stromal tumor-infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in patients with early breast cancer (BC) treated with neoadjuvant chemotherapy and HER2-directed therapies in NSABP B-41. Drug:Trastuzumab,lapatinib,Target:EGFR-TKI sensitizing...,HER2 (ERBB2),Organization:NSABP/NRG Oncology a...,Congress:ASCO 2024, Search all connections
Abstract A meta-analysis analyzing the efficacy of trastuzumab-deruxtecan (T-DXd) on central nervous system (CNS) disease in patients with metastatic breast cancer (mBC). Drug:T-DM1,trastuzumab-deruxtec...,Organization:SUNY Upstate Univers...,SUNY Upstate Medical...,SUNY Upstate Medical...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results. Drug:Tucatinib,Trastuzumab,capecitabine,Organization:Berry Consultants, L...,Seagen,Cleveland Clinic Tau..., Search all connections
Abstract Clinicopathological characteristics and outcomes of patients with HER2-low breast cancer: 6-year ambispective cohort study from India. Drug:trastuzumab deruxtec...,trastuzumab deruxtec...,Organization:Kasturba Medical Col...,Manipal Academy of H...,Kasturba Medical Col...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Overestimation of survival in individuals with cancer treated in the real world with new cancer drugs: A population-based cohort study. Drug:bevacizumab,durvalumab,ipilimumab,Target:Bevacizumab,PD-1, Search all connections
Abstract Landscape of HER2-low breast cancer: Insights from a six-year study on incidence and clinicopathological characteristics. Drug:HER2 CAR-T,Organization:Saint Joseph Univers...,Hotel-Dieu de France,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract A meta-analysis of the difference in response to trastuzumab-deruxtecan (T-DXd) based on HER2 immunohistochemistry (IHC) in HER2 low metastatic breast cancer (mBC). Organization:SUNY Upstate Univers...,SUNY Upstate Medical...,SUNY Upstate Medical...,Target:HER2 (ERBB2),Drug:trastuzumab-deruxtec...,Congress:ASCO 2024, Search all connections
Abstract A phase Ia/b trial of ARX788 combined with toripalimab for HER2-low advanced breast cancer (ABC) and other HER2-expressing solid tumors. Drug:ARX788,Toripalimab (Loqtorz...,capecitabine,Target:PD-1,Organization:Department of Breast...,Cancer Hospital of t...,Center of Hepato-Pan..., Search all connections
Abstract Prevalence of “HER2 ultra-low” among patients with advanced breast cancer with historical IHC0 status. Drug:trastuzumab deruxtec...,Organization:nference Inc.,AstraZeneca LLC,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Treatment (Tx) patterns, efficacy and safety of eribulin for advanced and heavily pretreated breast cancer (ABC): Updated results from a single-center, real-world study. Drug:eribulin,bevacizumab,capecitabine,Target:taxane,Topoisomerase II, Search all connections
Abstract Antibody-drug conjugates (ADC) in patients with advanced/metastatic HER2-low expressing breast cancer: A systematic review and meta-analysis. Drug:trastuzumab deruxtec...,Sacituzumab goviteca...,MRG002,Organization:Catholic University ...,Pelotas, Brazil,Universidade Estadua..., Search all connections
Abstract Real-world data comparison of time to next treatment for patients with HER2 low metastatic treated with either chemotherapy or fam-trastuzumab deruxtecan-nxki following chemotherapy in the metastatic setting. Drug:TDxd,paclitaxel,capecitabine,Target:capecitabine,DNA,Gemcitabine, Search all connections
Abstract CNS efficacy of trastuzumab deruxtecan in metastatic breast cancer: A single-institution, real-world analysis. Drug:trastuzumab deruxtec...,trastuzumab deruxtec...,Organization:UC San Diego,UC San Diego Moores ...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Identifying mutations in ctDNA to predict antibody-drug conjugate response in breast cancer. Drug:trastuzumab deruxtec...,Sacituzumab goviteca...,Target:TROP2,HER2 (ERBB2),Organization:UT Southwestern Medi...,Congress:ASCO 2024, Search all connections
Abstract Defining low-HER2 cancers using RNA quantification by next generation sequencing. Drug:trastuzumab-deruxtec...,Target:HER2 (ERBB2),Organization:John Theurer Cancer ...,Hackensack Medical C...,NJ, Search all connections
Abstract Efficacy and safety of dalpiciclib, fulvestrant, and pyrotinib in HR+ HER2-low advanced breast cancer following cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors and aromatase inhibitors (AIs): A Bayesian optimal phase II trial. Drug:pyrotinib,abemaciclib,palbociclib,Target:Estrogen Receptor (E...,CDK6,CDK4 & 6, Search all connections
Abstract Natural products to enhance anti-tumor effects of trastuzumab and paclitaxel on the SKBR3, which is human breast cancer cell line. Drug:Trastuzumab,paclitaxel,Biochanin A,Target:MAPK signaling pathw...,Organization:Dokuz Eylul Universi...,Izmir, Turkey,Izmir International ..., Search all connections
Abstract Effectiveness and safety of disitamab vedotin (RC48) in pretreated HER2-positive advanced breast cancer: A real-world experience in China. Drug:anti-microtubule che...,RC48,Trastuzumab,Target:microtubules,Organization:National Cancer Cent...,Internal Medicine-On...,The Second Affiliate..., Search all connections
Abstract Real-world data comparison of time to next treatment for patients with HER2 positive metastatic breast cancer treated in the second line of therapy with fam-trastuzumab deruxtecan-nxki or ado-trastuzumab emtansine. Drug:fam-trastuzumab ders...,ado-tratztozuri emtd...,tritzlizagal danov-t..., Search all connections
Abstract Interim safety analysis of phase IB trial of HER2 inhibitor tucatinib combined with PI3Kα inhibitor alpelisib in HER2+ PIK3CA-mutated metastatic breast cancer. Drug:Tucatinib,Alpelisib,Trastuzumab,Target:Estrogen Receptors (..., Search all connections
Abstract Trastuzumab-induced cardiotoxicity in patients with metastatic HER2-positive breast cancer treated at a reference hospital in Mexico. Drug:Trastuzumab,anthracyclines,Organization:Hospital de Oncologi...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Outcome with pertuzumab, docetaxel, and trastuzumab (PTH) regimen in patients with HER2 positive metastatic breast cancer: Real-world data from a single center in India. Drug:pertuzumab,docetaxel,Trastuzumab,Target:microtubules,HER2 (ERBB2),Organization:Associate Consultant,Congress:ASCO 2024, Search all connections
Abstract Safety and preliminary efficacy of GQ1001, a next generation HER2-targeting ADC, combined with pyrotinib in pretreated patients with HER2-positive metastatic breast cancer: A phase 1b clinical trial. Drug:GQ1001,Trastuzumab,DM1,Organization:Department of Medica...,Fudan University Sha..., Search all connections
Abstract Is early inclusion of neratinib with HER blockers possible in the treatment of stage 4 HER2 positive cancer? Drug:Trastuzumab,pertuzumab,neratinib,Target:tubulin,thymidylate synthase, Search all connections
Abstract The efficacy and safety of trastuzumab biosimilar HLX02 compared with reference trastuzumab plus pertuzumab in combination with chemotherapy as the first-line treatment for HER2 positive metastatic breast cancer: A real-world study in China. Drug:Trastuzumab,pertuzumab,HLX02,Target:paclitaxel, Search all connections
Abstract Unraveling the synergistic mechanisms of pyrotinib in combination with trastuzumab: Insights from the PHILA trial. Drug:pyrotinib,Trastuzumab,docetaxel,Organization:National Cancer Cent...,National Clinical Re...,Cancer Hospital of C..., Search all connections
Abstract T-DM1 in Chinese patients with Her2-positive metastatic breast cancer: A multi-center, retrospective, real world study. Drug:T-DM1,pyrotinib,lapatinib,Target:EGFR-TKI sensitizing...,HER2 (ERBB2),Organization:National Cancer Cent...,Shougang Beijing Uni..., Search all connections
Abstract Clinical efficacy of pyrotinib combined with stereotactic radiosurgery in HER2-positive breast cancer brain metastases. Drug:pyrotinib,Organization:Guanghzou, China,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Real-world analysis of inetetamab combined with pyrotinib plus chemotherapy for the treatment of HER2-positive advanced breast cancer: A multi-center retrospective study. Drug:inetetamab,tyrosine kinase inhi...,pyrotinib,Organization:The First Hospital o...,Zhangjiakou First Ho..., Search all connections
Abstract Evaluating the correlation between expression levels of carboxyl terminal modulator protein (CTMP) and the efficacy of trastuzumab in Syrian patients with HER2+ metastatic breast cancer. Target:CTMP,HER2 (ERBB2),Drug:Trastuzumab,docetaxel,vinorelbine,Organization:Damascus University,Syrian Arab Republic,Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety of HER2-ADC SHR-A1811 in HER2-positive breast cancer with brain metastases. Drug:SHR-A1811,pyrotinib,bevacizumab,Target:VEGF and c-MET pathw...,HER2 (ERBB2),Organization:Affiliated Cancer Ho...,Clinical trial:HNCH-MBC12,Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety of pyrotinib combined with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer (BC): A single-arm phase II trial. Drug:Tucatinib,lapatinib,T-DM1,Organization:Tianjin Cancer Hospi..., Search all connections
Abstract Pyrotinib plus taxanes or vinorelbine for human epidermal growth factor receptor 2-positive metastatic breast cancer: A prospective study. Drug:docetaxel,Nab-Paclitaxel,paclitaxel,Target:taxanes,Nab-Paclitaxel,paclitaxel, Search all connections
Abstract Efficacy and safety of disitamab vedotin (RC48) in HER2-expressing breast cancer: A multicenter retrospective study. Drug:RC48,Organization:Guizhou University o...,Affiliated Hospital ...,Department of Oncolo...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Heterogeneity of immune status in patient-derived malignant pleural effusion and ascites: Relationship to the ex-vivo efficacy of a HER2-targeted tri-specific antibody and a novel cytokine fusion protein. Drug:IAMA-004,IAMA-005,anti-PD1,Target:Herceptin,PD-1, Search all connections
Abstract Efficacy, safety, and predictive biomarkers of dalpiciclib combined with letrozole, pertuzumab and trastuzumab as neoadjuvant therapy in HR+/HER2+ breast cancer: A phase II study. Drug:tranduzumab,Trastuzumab,pertuzumab,Target:Cyclin dependent kin...,HER2 (ERBB2), Search all connections
Abstract Trastuzumab, pertuzumab and nab-paclitaxel plus pyrotinib or not in neoadjuvant treatment of HER2-positive breast cancer: A multi-center, randomized, open-label, phase II study. Drug:Trastuzumab,pertuzumab,pyrotinib,Target:microtubules,HER2 (ERBB2),Organization:Shangyu People's Hos...,Shaoxing, China, Search all connections
Abstract Efficacy and toxicity of trastuzumab emtansine among patients with HER-2-positive metastatic breast cancer in Saudi Arabia. Drug:trastuzumab emtansin...,Organization:King Faisal Speciali...,Alfaisal University ...,HCA Houston Healthca...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract A prospective, open-label, single-arm phase II clinical study of inetetamab in combination with pyrotinib and albumin-bound paclitaxel for the neoadjuvant treatment of patients with HER2+ early and locally advanced breast cancer. Drug:Inetetamab,pyrotinib,albumin-bound paclit..., Search all connections
Abstract PRE-ISPY phase I/Ib oncology platform program (PRE-I-SPY-P1). Drug:ALX-148,trastuzumab deruxtec...,Tucatinib,Target:Vidutolimod,PD-1, Search all connections
Abstract The relationship between PIK3CA mutations and survival in patients with human epidermal growth factor receptor 2–positive breast cancer receiving pyrotinib combined with trastuzumab for neoadjuvant treatment. Drug:pyrotinib,Trastuzumab,Organization:the Eighth Medical C...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety of recombinant humanized anti-HER2 antibody-MMAE conjugate (RC48) in neoadjuvant for HER2-positive breast cancer: A single-arm phase II study. Drug:RC48,EC,Trastuzumab,Organization:Air Force Medical Un...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Neoadjuvant pyrotinib and inetetamab in combination with chemotherapy for locally advanced HER2-positive breast cancer (NeoPICD study): A prospective, multicenter, open-label, single-arm study. Target:DNA,Drug:inetetamab,pyrotinib,carboplatin,Organization:Department of Thyroi...,Department of Breast..., Search all connections
Abstract A prospective phase II study of neoadjuvant therapy guided by personalized drug-testing on patient-derived tumor-like cell clusters for early breast cancer. Drug:taxanes,anthracyclines,carboplatin,Target:microtubules,Topoisomerase II,DNA, Search all connections
Abstract A propensity-matched analysis of the efficacy and safety of neoadjuvant inetetamab and pertuzumab with paclitaxel and carboplatin (TCbIP) on locally advanced HER2-positive breast cancer. Drug:Inetetamab,Trastuzumab,pertuzumab,Target:paclitaxel,DNA,Organization:National Cancer Cent..., Search all connections
Abstract Efficacy and safety of neoadjuvant trastuzumab, pyrotinib, and dalpiciclib without chemotherapy in early-stage HR-negative/HER2-positive breast cancer: An open-label, single-arm phase II trial. Drug:dalpiciclib,Trastuzumab,pyrotinib,Target:CDK6,CDK4 & 6,Organization:The First People's H...,Xiangtan,ShaoYang Central Hos..., Search all connections
Abstract Effect of neratinib on HER2 mRNA stability via hsa-miR-23a-5p and efficacy of CDK4/6 inhibitors in HER2-low breast cancer. Drug:CDK4/6 inhibitors,neratinib,actinomycin D,Target:CDK6,CDK4 & 6,HER2 (ERBB2),Organization:The Second Clinical ...,Congress:ASCO 2024, Search all connections
Abstract HER2 low hormone positive breast cancer: Unveiling the driver. Drug:trastuzumab deruxtec...,Organization:Medical Research Ins...,University of Alexan...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Optimal neoadjuvant treatment and prognostic factors in patients with HR-positive/HER2-positive early or locally advanced breast cancer: A national real-world study in China. Drug:Trastuzumab,pertuzumab,platinum-based chemo...,Target:DNA topoisomerase II,DNA,Organization:Department of Breast..., Search all connections
Abstract Real-world safety and discontinuation rates of fam-trastuzumab deruxtecan in advanced HER2-positive and HER2-low cancer. Drug:Enhertu,Organization:University of Kansas...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC). Drug:ARX788,Amberstatin 269,Trastuzumab,Target:tubulin,Organization:Hospital of Xinjiang..., Search all connections
Abstract The impact of adjuvant endocrine therapy (AET) omission in ER-low (1-10%) early-stage breast cancer. Drug:Adjuvant endocrine t...,Adjuvant endocrine t...,Target:Estrogen Receptor (E...,progesterone recepto...,HER2 (ERBB2),Organization:Mayo Clinic,Mayo Clinic Departme...,Congress:ASCO 2024, Search all connections
Abstract Pilot evaluation of portable scalp cooling for chemotherapy-associated alopecia in early-stage breast cancer. Drug:docetaxel,cyclophosphamide,paclitaxel,Target:docetaxel,paclitaxel,DNA, Search all connections
Abstract Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies. Organization:Samsung Medical Cent...,International Breast...,Pangaea Oncology, Search all connections
Abstract Predictors of cardiotoxicity in patients with early breast cancer treated with doxorubicin and/or trastuzumab: Implications of race/ethnicity and insurance status. Drug:doxorubicin,Trastuzumab,Target:Topoisomerase II,HER2 (ERBB2),Organization:Advocate Aurora Heal...,Congress:ASCO 2024, Search all connections
Abstract Off-label use of fam-trastuzumab deruxtecan-nxki with early activity in a cohort of patients with desmoplastic small round cell tumor. Drug:fam-trastuzumab deru...,trastuzumab-deruxtec...,Target:ERBB2,HER2 (ERBB2),Organization:Memorial Sloan Kette...,Congress:ASCO 2024, Search all connections
Abstract Evaluating antitumor activity and response determinants to trastuzumab deruxtecan in pediatric solid tumors. Drug:trastuzumab deruxtec...,DXd,trastuzumab-deruxtec...,Organization:Memorial Sloan Kette...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002). Drug:furmonertinib,gefitinib,Target:EGFR-TKI sensitizing...,Organization:Next Oncology Virgin...,Henry Ford Cancer In...,UC Davis Comprehensi..., Search all connections
Abstract Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations. Drug:zongertinib,pemetrexed,Cisplatin,Target:Programmed death-1 (...,Glycinamide Ribonucl...,Dihydrofolate reduct..., Search all connections
Abstract Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase I/II study. Drug:BAY 2927088,Target:EGFR-TKI sensitizing...,Organization:Shanghai Lung Cancer...,Department I of Thor...,Nanjing Drum Tower H..., Search all connections
Abstract Clinical impact of the rapid genomic screening platform for non-small cell lung cancer in Asia-Pacific (LC-SCRUM-AP). Drug:EGFR,KRAS,ALKi, Search all connections
Abstract Mefatinib as first-line treatment of EGFR sensitizing mutation-positive non-small-cell lung cancer: A phase III efficacy and biomarker study. Drug:mefatinib,gefitinib,Target:EGFR-TKI sensitizing...,HER2 (ERBB2),Organization:Huadong Medicine Co....,Huadong Global Devel...,HangZhou ZhongMei Hu...,Congress:ASCO 2024, Search all connections
Abstract Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02. Target:HER2 (ERBB2),Organization:Nantes University Ho...,Azienda Ospedaliero-...,Clinical trial:DS8201-A-U206,Drug:trastuzumab-deruxtec...,Congress:ASCO 2024, Search all connections
Abstract Characterization of HER2 alterations in lung adenocarcinoma. Drug:trastuzumab deruxtec...,Organization:Temple University Ho...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early stage lung cancer (LEADER) screening trial. Drug:EGFR,KRAS G12C,BRAF V600E, Search all connections
Abstract Pyrotinib in HER2-altered advanced salivary gland carcinomas: Analysis of two cohorts from an exploratory study. Drug:pyrotinib,Target:HER1,HER4,HER2 (ERBB2),Organization:Department of Oral a...,Shanghai Ninth Peopl...,Congress:ASCO 2024, Search all connections
Abstract Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02). Drug:trastuzumab deruxtec...,Organization:Hadassah Medical Mos...,Srinagarind Hospital,Chris O’Brien Lifeho...,Target:HER2 (ERBB2),Clinical trial:D967VC00001,Congress:ASCO 2024, Search all connections
Abstract AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC). Drug:Atezolizumab,lenvatinib,talazoparib, Search all connections
Abstract Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026). Drug:Trastuzumab,hyaluronidase-oysk,pertuzumab,Target:pertuzumab,tubulin, Search all connections
Abstract Analysis of healthcare provider treatment of advanced endometrial cancer and concordance with expert recommendations in 2023 vs 2022. Organization:David Geffen School ...,Drug:carboplatin,Tiragolumab,Immune checkpoint in...,Target:CTLA-4, Search all connections
Abstract SAVE: A prospective, single-arm, single-center clinical study of disitamab vedotin in combination with toripalimab in patients with advanced penile cancer that has progressed or is intolerant to cisplatin chemotherapy. Drug:paclitaxel,ifosfamide,Cisplatin, Search all connections
Abstract Adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 overexpression: A phase II multi-center study. Drug:Bacillus Calmette-Gu...,Disitamab vedotin,Organization:The First Affiliated...,Target:HER2 (ERBB2),Clinical trial:2023(24),Congress:ASCO 2024, Search all connections
Abstract Phase 3 study of disitamab vedotin with pembrolizumab vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001). Drug:Enfortumab vedotin,pembrolizumab,Disitamab vedotin,Target:Programmed cell deat...,Nectin-4, Search all connections
Abstract Preliminary efficacy and safety results from RC48-C017: A phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression. Drug:Disitamab vedotin,Toripalimab (Loqtorz...,Target:PD-1,HER2 (ERBB2),Organization:School of Life Scien...,Clinical trial:RC48-C017,Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study. Drug:trastuzumab deruxtec...,Organization:Jagiellonian Univers...,Kraków,N.N Blokhin National..., Search all connections
Abstract Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with MAPK pathway alterations: A ComboMATCH treatment trial. Drug:Gemcitabine,Cisplatin,5-Fluorouracil,Target:BRAFV600E, Search all connections
Abstract A randomized, open-label phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF633/DANTE trial, a trial of AIO in collaboration with SAKK. Drug:Atezolizumab,FLOT,Target:VEGFR-1,EGFR-TKI sensitizing...,HER3,Organization:University Cancer Ce...,St. Anna Hospital He..., Search all connections
Abstract A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors. Drug:Valemetostat,Dato-DXd,Target:EZH1,EZH2,HER2 (ERBB2),Organization:National Cancer Cent...,Daiichi Sankyo Ltd.,Clinical trial:DS3201-324, Search all connections
Abstract Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02). Drug:trastuzumab deruxtec...,DS-8201a,trastuzumab deruxtec...,Organization:Maria Skłodowska-Cur...,Hôtel-Dieu de Québec,Clinical Hospital “R...,Target:HER2 (ERBB2), Search all connections
Abstract Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study. Drug:zanidatamab,Gemcitabine,Target:ribonucleotide reduc...,deoxycytidine kinase,Organization:Zhongshan Hospital o...,Seoul National Unive...,Yonsei Cancer Center..., Search all connections
Abstract Phase II randomized study of maintenance therapy with regorafenib (REGO) versus placebo after first-line platinum and fluoropyrimidines-based chemotherapy in HER2 negative locally advanced/metastatic gastric (GC) or gastroesophageal junction (GEJ) cancer: Results of a-MANTRA study (GOIRC-05-2016). Drug:Regorafenib,Target:VEGFR-1,EGFR-TKI sensitizing...,Organization:Reggio Emilia,Potenza,Italy - Reggio Emili..., Search all connections
Abstract Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. Drug:zolbetuximab,folinic acid,5-FU,Target:5-FU,oxaliplatin,CLDN18.2, Search all connections
Abstract Use of circulating tumor DNA (ctDNA) to affect the adjuvant or post-adjuvant treatment of patients with stage III and high-risk stage II resected colon cancer: The ERASE-CRC project by GONO. Drug:fluoropyrimidines,oxaliplatin,FOLFOX6, Search all connections
Abstract Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in patients (pts) with pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A translational analysis of the TRIPLETE trial. Drug:FOLFOX6,panitumumab,mFOLFOXIRI,Target:BRAF,MAP2K1,PTEN, Search all connections
Abstract Deciphering tumor microenvironment dynamics in HER2-amplified refractory metastatic colorectal cancer in the TRIUMPH trial. Drug:Trastuzumab,pertuzumab,pertuzumab,Organization:Hiroshima University...,Department of Surger...,Department of Gastro..., Search all connections
Abstract Therapeutic implications of acquired high tumor mutational burden (TMB-H) after targeted therapy (TT) in metastatic colorectal cancer (mCRC). Drug:EGFR,BRAF V600E,KRAS G12C, Search all connections
Abstract IAM1363-01: A phase 1/1b study of a selective and brain-penetrant HER2 inhibitor for HER2-driven solid tumors. Drug:IAM1363,Trastuzumab,Organization:Iambic Clinical Advi...,Target:HER2 (ERBB2),Clinical trial:IAM1363-01,Congress:ASCO 2024, Search all connections
Abstract An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, and pharmacokinetics of VIP236 monotherapy in patients with advanced cancer. Drug:VIP236,VIP126,trastuzumab deruxtec...,Target:αvβ3 integrin,neutrophil elastase,neutrophil elastase, Search all connections
Abstract Genomics to select treatment for patients (pts) with metastatic cancer: Final analysis of Molecular Tumor Board (MTB) evaluations in the ROME trial. Drug:ipilimumab,nivolumab,PI3K, Search all connections
Abstract Phase II study to evaluate safety and efficacy of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors (KCSG AL20-17). Drug:neratinib,Trastuzumab,Organization:Division of Hematolo...,Target:HER2 (ERBB2),Clinical trial:AL20-17,Congress:ASCO 2024, Search all connections
Abstract Prevalence of recreational and medical cannabis products in Veterans and their interactions with cancer directed pharmacological treatment. Drug:cannabis,immunotherapy,chemotherapy,Target:chemotherapy,CYP450,endocrine therapy, Search all connections
Abstract Phase Ia/Ib trial on the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M). Drug:Mobocertinib,T-DM1,Organization:Division of Medical ...,Department of Oncolo...,Department of Clinic...,Target:HER2 (ERBB2), Search all connections
Abstract The design, preclinical study and phase I dose escalation plan of a HER2 targeted immunoliposome (HF-K1) for HER2 low solid tumor treatment. Drug:doxorubicin,PEG-coated liposomes,immunoliposomes,Organization:Hangzhou HighField B..., Search all connections
Abstract Safety and efficacy of JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study. Drug:JSKN003,Organization:Blacktown Hospital,Hollywood Private Ho...,Liverpool Hospital,Target:HER2 (ERBB2),Clinical trial:JSKN003-101,Congress:ASCO 2024, Search all connections
Abstract Evaluation of the safety, pharmacokinetics, and efficacy of JSKN003 in patients with advanced solid tumors: A phase I/II clinical study. Drug:JSKN003,JSKN003,Target:topoisomerase I,HER2 (ERBB2),Organization:Department of Breast...,2nd Hospital, Zhejia...,Department of Medica...,Clinical trial:JSKN003-102, Search all connections
Abstract Safety and efficacy of biosimilar TDM-1: A real world retrospective study. Drug:Ado-Trastuzumab emta...,TDM1,biosimilar TDM1,Target:Thrombopoietin recep...,HER2 (ERBB2),Organization:Basavatarakam Indo-A...,Hyderabad, Search all connections
Abstract A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors. Drug:CT-0508,pembrolizumab,CT-0525,Target:Programmed cell deat...,Granulocyte colony-s...,HER2 (ERBB2),Organization:Division of Hematolo..., Search all connections
Abstract Effect of placental circulating T cells expressing CD16 on multiple hematological and solid tumor cancers through combination with various monoclonal antibodies. Drug:PT-CD16VS,rituximab,Trastuzumab,Target:TCR,EGFR-TKI sensitizing...,CD16A, Search all connections
Abstract Use of IL-3RB to mediate antitumor effect of CAR-T cells through the JAK-STAT signaling pathway. Drug:HER2 CAR-T,VEGFR1 CAR-T,IL-3RB,Target:IL-3 receptor β chai...,VEGFR1,Organization:Thoracic Oncology Wa...,Institute of Medical...,Peking University He..., Search all connections
Abstract A first-in-human phase 1 trial of dose escalating intrathecal (IT) dendritic cells (cDC1s) primed against HER2/HER3 in patients (pts) with leptomeningeal disease (LMD) from triple-negative (TNBC) or HER2+ breast cancer (BC). Drug:cDC1,Target:HER3,Organization:H. Lee Moffitt Cance...,Tampa, FL,Roswell Park Compreh..., Search all connections
Abstract Efficacy of intrathecal delivery of peptide-pulsed type 1 conventional dendritic cell vaccine for the treatment of breast cancer-associated leptomeningeal disease in preclinical models. Organization:H. Lee Moffitt Cance...,Roswell Park Compreh...,Drug:Trastuzumab,Target:HER2 (ERBB2),Clinical trial:MCC-21262,Congress:ASCO 2024, Search all connections
Abstract Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV. Organization:LMU University Hospi...,Interdisciplinary Br...,Rotkreuz-Clinics Mun..., Search all connections
Abstract Neoadjuvant targeted therapy in early resectable HER2-mutant lobular breast cancer. Organization:Vanderbilt-Ingram Ca...,University of Texas ...,UT Southwestern Simm...,Drug:neratinib,endocrine therapy,Target:ERBB2,HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer. Organization:University of Kansas...,Department of Biosta...,St. Luke’s Universit..., Search all connections
Abstract RAGE inhibition to decrease cancer therapy related cardiotoxicity in women with early breast cancer (RAGE). Organization:Medstar Georgetown U...,Lombardi Cancer Cent...,Regional Cancer Care...,Drug:anthracyclines,TTP488, Search all connections
Abstract Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in patients with breast cancer with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy: Flamingo-01. Organization:Greenwich LifeScienc...,Stafford, TX,Lester and Sue Smith...,Drug:GLSI-100,Trastuzumab, Search all connections
Abstract Assessing the feasibility and cost-effectiveness of all oral adjuvant chemotherapy (cyclophosphamide, methotrexate, capecitabine) in high-risk hormone receptor positive breast cancer. Organization:University of Illino...,University of Illino...,Stanford University ...,Drug:cyclophosphamide,methotrexate,capecitabine,Target:dihydrofolate reduct...,thymidylate synthase, Search all connections
Abstract Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy: ECOG-ACRIN EA1211/DIRECT trial. Organization:Cancer Research @UCC,Brown University - E...,Dana-Farber Cancer I..., Search all connections
Abstract A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009. Organization:Georgetown Lombardi ...,Georgetown Universit...,MedStar Health, Search all connections
Abstract ECLECTIC: 18F-fluoroestradiol PET and circulating biomarkers to guide the choice of the second line therapy for ER+, HER2- metastatic breast cancer: A phase 3 trial. Organization:Institut Curie, Sain...,Paris and Saint Clou...,France, Search all connections
Abstract INAVO122: A phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with PIK3CA-mutated, HER2-positive advanced breast cancer (HER2+ aBC). Organization:Genentech,Product Development ...,F. Hoffmann-La Roche..., Search all connections
Abstract ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd). Organization:The University of Te...,US Oncology Research...,Norton Healthcare, Search all connections
Abstract An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC). Organization:UCLA Health Jonsson ...,Mayo Clinic,Miami Cancer Institu..., Search all connections
Abstract Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd). Organization:Stanford University ...,University of Miami ...,Stanford University ..., Search all connections
Abstract Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in patients with HER2 low/ultra-low/null metastatic breast cancer. Organization:University of Hawaii...,The University of Te...,Department of Invest...,Drug:trastuzumab deruxtec...,Valemetostat,Target:Enhancer of zeste ho...,Schlafen11 (SLFN11),Enhancer of zeste ho..., Search all connections
Abstract Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): Primary analysis of a prospective, multicenter, response-adapted study. Organization:Second Hospital of S...,Affiliated Hospital ...,Binzhou Medical Univ..., Search all connections
Abstract Neoadjuvant pegylated liposomal doxorubicin-containing chemotherapy in combination with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer: A randomized phase II study (METIS). Organization:Department of Medica...,State Key Laboratory...,Collaborative Innova..., Search all connections
Abstract Multiomic factor analysis for pathologic complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched (HER2-E) early breast cancer (eBC) in the Keyriched-1 trial. Organization:West German Study Gr...,Moenchengladbach, Ge...,Queen Mary Universit..., Search all connections
Abstract Prevalence and dynamics of circulating tumor DNA (ctDNA) among patients (pts) with HER2+ breast cancer (BC) receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) in the DAPHNe trial. Organization:Dana-Farber Cancer I...,Harvard Medical Scho...,Boston, MA, Search all connections
Abstract Comparing 18F-FDG positron emission tomography (PET) and breast magnetic resonance imaging (MRI) to predict pathological complete response (pCR) and 3-year invasive disease-free survival (3-y iDFS) in patients (pts) with HER2+ early breast cancer (EBC): An unplanned exploratory analysis of PHERGain trial. Organization:International Breast...,Pangaea Oncology,Quiron Group, Search all connections
Abstract Patient-derived tumor cell clusters (PTC) guiding-neoadjuvant therapy of HER2-positive breast cancer: A prospective randomized phase II clinical trial. Organization:Zhejiang Cancer Hosp...,Hangzhou, China,Drug:cyclophosphamide,Epirubicin,docetaxel, Search all connections
Abstract Molecular profiling after short-term preoperative endocrine therapy to identify oestrogen receptor positive (ER+)/HER2+ early breast tumours with favourable prognosis. Organization:Institute of Cancer ...,Royal Marsden Hospit...,The Institute of Can..., Search all connections
Abstract Safety run-in phase of the multi-epitope HER2 peptide vaccine in combination with trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy. Organization:Mayo Clinic Florida,Mayo Clinic,Mayo Clinic Alliance...,Drug:trastuzumab emtansin...,T-DM1,H2NVAC, Search all connections
Abstract Clinical outcomes of patients with HER2-positive microinvasive breast cancer. Organization:Department of Oncolo...,Asan Medical Center,University of Ulsan ...,Drug:Trastuzumab,paclitaxel, Search all connections
Abstract Relevance of timing intake of everolimus (EVE) combined with adjuvant endocrine therapy (ET) in patients (pts) with high-risk early breast cancer: Results of a sub-study of the UCBG-UNIRAD trial. Organization:Surgery Department,Institut Curie, Sain...,Universite Paris Cit..., Search all connections
Abstract Predicting epirubicin response in Danish patients with breast cancer. Organization:Aida Oncology,Dragor, Denmark,JADBio, Search all connections
Abstract Financial toxicity in patients with metastatic breast cancer on trastuzumab deruxtecan (T-DXd). Organization:Department of Radiat...,School of Social Wor...,Department of Obstet..., Search all connections
Abstract Tucatinib and trastuzumab for previously treated HER2−mutated metastatic breast cancer (SGNTUC−019): A phase 2 basket study. Organization:The Royal Marsden NH...,Istituto Europeo di ...,IRCCS and University..., Search all connections
Abstract Efficacy and genomic analysis of HER2-mutant, metastatic triple-negative breast cancer treated with neratinib alone or in combination with trastuzumab in the phase 2 SUMMIT basket trial. Organization:Memorial Sloan Kette...,University of Washin...,University of Pittsb..., Search all connections
Abstract Results and exploratory biomarker analyses of a phase II study CHANGEABLE: Combination of HX008 and niraparib in germ-line-mutated metastatic breast cancer. Organization:Department of Medica...,Department of Oncolo...,Department of Oncolo...,Drug:niraparib,HX008, Search all connections
Abstract Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age, sites of disease, and use of intervening therapies. Organization:University of Califo...,Miami Cancer Institu...,Baptist Health South..., Search all connections
Abstract Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer. Organization:Dana-Farber Cancer I...,Yale School of Medic...,University of Pittsb...,Target:HER2 (ERBB2),Drug:trastuzumab-deruxtec..., Search all connections
Abstract LEONARDA-2: Lerociclib plus letrozole versus placebo plus letrozole in HR+/HER2- advanced or metastatic breast cancer. Organization:Genor Biopharma Co.,...,Genor Biopharma,Genor Biopharma Co.,...,Drug:lerociclib,letrozole,Target:Hormone Receptor (HR...,Estrogen Receptor 1 ..., Search all connections
Abstract Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan. Organization:Miami Cancer Institu...,Baptist Health South...,Guardian Research Ne...,Drug:trastuzumab deruxtec...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract [68Ga]Ga-ABY-025 PET in HER2-positive breast cancer: Benefits and pitfalls in staging of axillary disease. Organization:Department of Immuno...,Radiology, Departmen...,Affibody AB, Stockho...,Drug:68Ga-Ga-ABY-025,18F-FDG,Target:Glucose transporter ...,HER2 (ERBB2), Search all connections
Abstract Safety and efficacy of trastuzumab deruxtecan for metastatic HER2+ and HER2-low breast cancer: An updated systematic review and meta-analysis of clinical trials. Organization:The Frank H. Netter ...,Bridgeport, CT,BronxCare Health Sys...,Drug:trastuzumab deruxtec..., Search all connections
Abstract Trastuzumab deruxtecan in patients with breast cancer with brain metastases: The DE-REAL study. Organization:Department of Experi...,Precision Medicine U...,Precision Medicine i..., Search all connections
Abstract The subgroup analysis by age and geriatric assessment in a phase III study comparison of trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in older patients with advanced stage HER2-positive breast cancer (JCOG1607 HERB TEA study). Organization:National Center for ...,Shimane University H...,Japan Clinical Oncol..., Search all connections
Abstract Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study. Organization:Memorial Sloan Kette...,University of Vermon...,Université Libre de ..., Search all connections
Abstract Preliminary safety and efficacy of TQB2930, a HER2-targeted bispecific antibody in patients with advanced breast cancer: Results from a phase 1b study. Organization:Department of Medica...,Harbin Medical Unive...,Chongqing University..., Search all connections
Abstract Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03. Organization:Sarah Cannon Researc...,University of Washin...,Seoul National Unive..., Search all connections
Abstract Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01, -02, and -03. Organization:Vall d’Hebron Univer...,Vall d'Hebron Instit...,International Breast..., Search all connections
Abstract Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter, single-arm, phase II trial (RCTS). Organization:Qilu Hospital of Sha...,The Affiliated Hospi...,The Third Hospital o..., Search all connections
Abstract FU/FA maintenance therapy with or without panitumumab (pmab) in RAS wild-type metastatic colorectal cancer (mCRC) (PanaMa, AIO KRK 0212): Updated efficacy analyses. Organization:Charité-Universitäts...,Freie Universität Be...,Humboldt-Universität..., Search all connections
Abstract A randomized study comparing electronic patient-reported outcome (ePRO) monitoring with routine follow-up during trastuzumab deruxtecan treatment in patients with metastatic breast cancer (PRO-DUCE study). Organization:Department of Breast...,Center for Clinical ...,Department of Oncolo..., Search all connections
Abstract Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). Organization:University of Milan ...,Fudan University Sha...,Division of Medical ..., Search all connections
Abstract DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC. Organization:Gustave Roussy Cance...,Université Paris-Sac...,Villejuif, France, Search all connections
Abstract Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer. Organization:SOLTI Cancer Researc...,Department of Medica...,Translational Genomi..., Search all connections
Abstract Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD). Organization:Kanagawa Cancer Cent...,Fukushima Medical Un...,Cancer Institute Hos..., Search all connections
Abstract AI-based HER2-low IHC scoring in breast cancer across multiple sites, clones, and scanners. Organization:Institute of Patholo...,Institute of Patholo...,Mindpeak GmbH, Search all connections
Abstract ECOG-ACRIN E2197: Comparison of HER2 gene expression by RT-PCR across all HER2 immunohistochemistry groups with recurrence analysis. Organization:Exact Sciences Corpo...,Genomic Health Inc,Fred Hutchinson Canc..., Search all connections
Abstract Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival. Organization:University of Califo...,University of Califo...,University of Texas ..., Search all connections
Abstract Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study. Organization:Harvard Medical Scho...,Massachusetts Genera...,Dana-Farber Cancer I...,Drug:Sacituzumab goviteca...,trastuzumab deruxtec...,Target:HER2 (ERBB2),Trop-2, Search all connections
Abstract HER2-low status discordance between primary and recurrent/metastatic breast cancer in a large-scale cohort. Organization:Fudan University Sha...,China National Biote...,West China Hospital, Search all connections
Abstract Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04. Organization:Memorial Sloan Kette...,Kanagawa Cancer Cent...,Severance Hospital, Search all connections
Abstract The association of centromere amplification and response to trastuzumab in HER2+ metastatic breast cancer. Organization:School of Biotechnol...,Medical Oncology Dep...,CCRT/The Caroline Fo..., Search all connections
Abstract Pertuzumab retreatment in patients with HER2-positive locally advanced/metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS). Organization:Aichi Cancer Center ...,Osaka University Gra...,Department of Breast..., Search all connections
Abstract The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program. Organization:Durham, NC,Labcorp Oncology,Nykode Therapeutics, Search all connections
Abstract Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001). Organization:Narayana Multispecia...,Tata Memorial Hospit...,Homi Bhabha cancer h..., Search all connections
Abstract Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2‑amplified biliary tract cancer (BTC). Organization:Zymeworks BC,BeiGene Ltd.,Product:Zanidatamab,Target:HER2 (ERBB2),ribonucleotide reduc...,Drug:zanidatamab,FF-10832,Clinical trial:ZWI-ZW25-203, Search all connections
Abstract Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study. Organization:National Cancer Cent...,St. Marianna Univers...,Kindai University Fa..., Search all connections
Abstract Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. Organization:Daiichi Sankyo Co, L...,Daiichi Sankyo Inc.,Product:Trastuzumab deruxtec...,Target:HER2 (ERBB2),Drug:Trastuzumab,trastuzumab-deruxtec...,Clinical trial:DS8201-A-U207,Congress:ASCO 2023, Search all connections
Abstract Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. Organization:Memorial Sloan Kette...,Seoul National Unive...,Cancer Center Clínic..., Search all connections
Abstract Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results. Organization:Centre Léon Bérard,Centre Hospitalier d...,Centre Oscar Lambret, Search all connections
Abstract 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC). Organization:International Breast...,Pangaea Oncology,Quiron Group, Search all connections
Abstract Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials. Organization:NSABP,Dana-Farber Cancer I...,University of Michig..., Search all connections
Abstract Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial. Organization:Westwood,Kansas City,Department of Biosta..., Search all connections
Abstract An age-specific pooled analysis of trastuzumab deruxtecan (T‑DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03. Organization:University Hospital ...,International Breast...,Quironsalud Group, Search all connections
Abstract Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies. Organization:Massachusetts Genera...,Massachusetts Genera...,Dana-Farber Cancer I...,Product:Trastuzumab deruxtec...,Target:HER2 (ERBB2),Drug:trastuzumab deruxtec...,Congress:ASCO 2023, Search all connections